BeOne Medicines Ltd.
百濟神州有限公司

(a corporation incorporated under the laws of Switzerland)

(Stock Code: 06160)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025

BeOne Medicines Ltd. together with its subsidiaries (the "Company" or "BeOne" or "we" or "us") hereby announces the unaudited condensed consolidated results of the Company for the six months ended June 30, 2025 (the "Reporting Period"), together with the comparative figures for the corresponding period in 2024, which have been prepared under generally accepted accounting principles in the United States (the "U.S. GAAP" or "GAAP") and reviewed by the audit committee (the "Audit Committee") of the Board of Directors (the "Board" or "Directors") of the Company.

FINANCIAL HIGHLIGHTS

- Total revenues for the six months ended June 30, 2025 increased by approximately US$751.8 million or approximately 44.7% to approximately US$2,432.6 million, as compared to the six months ended June 30, 2024. Product revenue increased by approximately US$742.5 million or approximately 44.5% to approximately US$2,410.6 million, as compared to the six months ended June 30, 2024.

- Total operating expenses for six months ended June 30, 2025, increased by approximately US$217.7 million or approximately 12.2% to approximately US$2,004.0 million, as compared to the six months ended June 30, 2024.

- Net income for the six months ended June 30, 2025 was approximately US$95.6 million, as compared to net loss of approximately US$371.6 million for the six months ended June 30, 2024.

- Basic and diluted earnings per share for the six months ended June 30, 2025 was US$0.07 per share, compared to basic loss of US$0.27 per share for the six months ended June 30, 2024.

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	Note	Six Months Ended June 30, 2025 US$'000	2024 US$'000
Revenues			
Product revenue, net	13	2,410,606	1,668,064
Collaboration revenue	3	21,973	12,754
Total revenues		2,432,579	1,680,818
Cost of sales – product		329,608	263,067
Gross profit		2,102,971	1,417,751
Operating expenses			
Research and development		1,006,783	915,104
Selling, general and administrative		997,201	871,156
Total operating expenses		2,003,984	1,786,260
Income (loss) from operations		98,987	(368,509)
Interest income, net		9,345	29,385
Other income (expense), net		12,117	(10,222)
Income (loss) before income taxes		120,449	(349,346)
Income tax expense	9	24,859	22,209
Net income (loss)		95,590	(371,555)
Earnings (loss) per share (in US$)			
Basic	15	0.07	(0.27)
Diluted	15	0.07	(0.27)
Weighted-average shares outstanding – basic		1,399,159,898	1,358,315,145
Weighted-average shares outstanding – diluted		1,454,296,475	1,358,315,145
Earnings (loss) per American Depositary Share ("ADS") (in US$)			
Basic	15	0.89	(3.56)
Diluted	15	0.85	(3.56)
Weighted-average ADSs outstanding – basic		107,627,684	104,485,780
Weighted-average ADSs outstanding – diluted		111,868,960	104,485,780

The accompanying notes are an integral part of these condensed consolidated financial statements.

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

	Note	Six Months Ended June 30, 2025 US$'000	2024 US$'000
Net income (loss)		95,590	(371,555)
Other comprehensive income (loss), net of tax of nil:			
Foreign currency translation adjustments	17	34,988	(41,399)
Other adjustments	17	302	371
Comprehensive income (loss)		130,880	(412,583)

The accompanying notes are an integral part of these condensed consolidated financial statements.

UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS

	Note	As of June 30, 2025 US$'000 (unaudited)	As of December 31, 2024 US$'000 (audited)
Assets			
Current assets:			
Cash and cash equivalents		2,756,056	2,627,410
Accounts receivable, net	5	770,776	676,278
Inventories, net	6	502,867	494,986
Prepaid expenses and other current assets	10	280,522	192,919
Total current assets		4,310,221	3,991,593
Property, plant and equipment, net	7	1,615,792	1,578,423
Operating lease right-of-use assets		145,769	139,309
Intangible assets, net	8	64,890	51,095
Other non-current assets	10	161,722	160,490
Total non-current assets		1,988,173	1,929,317
Total assets		6,298,394	5,920,910
Liabilities and shareholders' equity			
Current liabilities:			
Accounts payable	11	360,783	404,997
Accrued expenses and other payables	10	908,882	803,713
Tax payable	9	5,536	25,930
Operating lease liabilities, current portion		17,250	17,576
Research and development cost share liability, current portion	3	108,992	111,154
Short-term debt	12	808,394	851,529
Total current liabilities		2,209,837	2,214,899

The accompanying notes are an integral part of these condensed consolidated financial statements.

UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (CONTINUED)

	Note	As of June 30, 2025 US$'000 (unaudited)	As of December 31, 2024 US$'000 (audited)
Non-current liabilities:			
Long-term debt	12	146,091	166,484
Operating lease liabilities, non-current portion		53,940	44,277
Deferred tax liabilities	9	44,093	42,007
Research and development cost share liability, non-current portion	3	10,879	54,286
Other long-term liabilities	10	63,079	66,735
Total non-current liabilities		318,082	373,789
Total liabilities		2,527,919	2,588,688
Commitments and contingencies	19		
Shareholders' equity:			
Ordinary shares, US$0.0001 par value per share; 1,540,975,898 and 1,387,367,704 shares issued and 1,428,203,304 and 1,387,367,704 shares outstanding as of June 30, 2025 and December 31, 2024, respectively		143	138
Additional paid-in capital		12,395,276	12,087,908
Accumulated other comprehensive loss	17	(113,698)	(148,988)
Accumulated deficit		(8,511,246)	(8,606,836)
Total shareholders' equity		3,770,475	3,332,222
Total liabilities and shareholders' equity		6,298,394	5,920,910

The accompanying notes are an integral part of these condensed consolidated financial statements.

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	Note	Six Months Ended June 30, 2025 US$'000	2024 US$'000
Operating activities:			
Net income (loss)		95,590	(371,555)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:			
Depreciation and amortization expense		68,418	50,224
Share-based compensation expenses	16	246,287	219,304
Acquired in-process research and development		500	–
Gain on deconsolidation of a subsidiary		–	(3,735)
Amortization of research and development cost share liability	3	(45,569)	(35,039)
Other items, net		15,128	5,413
Changes in operating assets and liabilities:			
Accounts receivable		(73,369)	(173,896)
Inventories		6,174	(35,949)
Other assets		(45,316)	(32,233)
Accounts payable		(35,852)	2,192
Accrued expenses and other payables		75,625	(28,256)
Other liabilities		64	(630)
Net cash provided by (used in) operating activities		307,680	(404,160)
Investing activities:			
Purchases of property, plant and equipment		(100,233)	(266,528)
Purchase of intangible asset		(20,000)	(4,674)
Proceeds from sale or maturity of investments		1,800	2,655
Purchase of in-process research and development		(60,000)	(31,800)
Other investing activities		(10,113)	(20,516)
Net cash used in investing activities		(188,546)	(320,863)

The accompanying notes are an integral part of these condensed consolidated financial statements.

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)

	Note	Six Months Ended June 30, 2025 US$'000	2024 US$'000
Financing activities:			
Proceeds from long-term loan	12	–	9,053
Repayment of long-term loan	12	(16,799)	(14,020)
Proceeds from short-term loans	12	221,521	324,412
Repayment of short-term loans	12	(275,782)	(157,490)
Payments of withholding taxes from share-based awards		(24,195)	–
Proceeds from option exercises and employee share purchase plan		96,503	20,355
Other financing activities		–	3,000
Net cash provided by financing activities		1,248	185,310
Effect of foreign exchange rate changes, net		26,957	(28,340)
Net increase (decrease) in cash, cash equivalents, and restricted cash		147,339	(568,053)
Cash, cash equivalents, and restricted cash at beginning of period		2,638,747	3,185,984
Cash, cash equivalents, and restricted cash at end of period		2,786,086	2,617,931
Supplemental cash flow information:			
Cash and cash equivalents		2,756,056	2,592,655
Short-term restricted cash		15,802	23,155
Long-term restricted cash		14,228	2,121
Income taxes paid		77,033	45,636
Interest expense paid		24,018	24,148
Supplemental non-cash information:			
Capital expenditures included in accounts payable and accrued expenses		57,923	115,564
ROU assets obtained in exchange for new operating lease liabilities		18,141	27,267
Increase in equity investment from deconsolidation of a subsidiary		–	40,798

The accompanying notes are an integral part of these condensed consolidated financial statements.

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY

	Ordinary Shares Issued	Effect of Redomiciliation[1] Shares	Total Outstanding Shares	Ordinary Shares Issued US$'000	Additional Paid-In Capital US$'000	Accumulated Other Comprehensive Loss US$'000	Accumulated Deficit US$'000	Total US$'000
Balance at December 31, 2024	1,387,367,704	–	1,387,367,704	138	12,087,908	(148,988)	(8,606,836)	3,332,222
Issuance of shares reserved for share option exercises[1]	109,709,434	(112,772,594)	(3,063,160)	–	–	–	–	–
Exercise of options, ESPP and release of RSUs	43,898,760	–	43,898,760	5	96,604	–	–	96,609
Share-based compensation	–	–	–	–	246,287	–	–	246,287
Withholding taxes from share-based awards	–	–	–	–	(35,523)	–	–	(35,523)
Other comprehensive income	–	–	–	–	–	35,290	–	35,290
Net income	–	–	–	–	–	–	95,590	95,590
Balance at June 30, 2025	1,540,975,898	(112,772,594)	1,428,203,304	143	12,395,276	(113,698)	(8,511,246)	3,770,475
Balance at December 31, 2023	1,359,513,224	–	1,359,513,224	135	11,598,688	(99,446)	(7,962,050)	3,537,327
Use of shares reserved for share option exercises	(1,216,016)	–	(1,216,016)	–	–	–	–	–
Exercise of options, ESPP and release of RSUs	20,804,693	–	20,804,693	2	20,153	–	–	20,155
Share-based compensation	–	–	–	–	219,304	–	–	219,304
Deconsolidation of a subsidiary	–	–	–	–	2,052	–	–	2,052
Other comprehensive loss	–	–	–	–	–	(41,028)	–	(41,028)
Net loss	–	–	–	–	–	–	(371,555)	(371,555)
Balance at June 30, 2024	1,379,101,901	–	1,379,101,901	137	11,840,197	(140,474)	(8,333,605)	3,366,255

1. Upon effectiveness of the redomiciliation to Switzerland, ordinary shares (including in the form of ADS) held by the Company or one of its controlled subsidiaries immediately prior to the effective date of the redomiciliation became part of the Company's issued but not outstanding share capital and are considered own ordinary shares of the Company, or "treasury shares," under Swiss law. The Company expects to use these treasury shares in the future to satisfy obligations to deliver shares in connection with awards granted under the Company's equity incentive plans and agreements.

The accompanying notes are an integral part of these condensed consolidated financial statements.

NOTES TO THE UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

1. Description of Business, Basis of Presentation and Consolidation and Significant Accounting Policies

Description of business

BeOne Medicines Ltd. (the "Company", "BeOne", "it", "its"), formerly known as BeiGene, Ltd., is a global oncology company redomiciled in Switzerland during the second quarter of 2025, that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide.

The redomiciliation to Switzerland did not change the accounting basis under U.S. GAAP of any of the Company's consolidated assets, liabilities, equity, or any previous results of operations or cash flows.

In connection with the redomiciliation, ordinary shares held by the Company or one of its controlled subsidiaries immediately prior to the effective date of the redomiciliation will be part of the Company's issued share capital and be considered own ordinary shares of the Company, or "treasury shares", under Swiss law. See the Company's final prospectus filed with the U.S. Securities and Exchange Commission pursuant to Rule 424(b)(3) and the proxy statement/circular filed with The Stock Exchange of Hong Kong Limited (the "HKEX") on March 10, 2025 for a full description of the changes related to the Company's ordinary shares resulting from the redomiciliation to Switzerland.

Since its inception in 2010, the Company has become a fully integrated global organization with more than 11,000 employees worldwide.

As of June 30, 2025, the Company had the following principal subsidiaries:

Name of Company	Place of Incorporation	Particulars of issued/ paid-in capital	Percentage of Ownership by the Company	Principal Activities and Place of Operation
BeOne Medicines (Beijing) Co., Ltd. (formerly known as BeiGene (Beijing) Co., Ltd.)	PRC*	RMB2,722,787,023	100%	Medical and pharmaceutical research and development, PRC
BeOne Guangzhou Biologics Manufacturing Co., Ltd. (formerly known as BeiGene Guangzhou Biologics Manufacturing Co., Ltd.)	PRC*	RMB16,113,108,600	100%	Medical and pharmaceutical research and development, manufacturing and commercialization, PRC
BeOne Medicines (Shanghai) Co., Ltd. (formerly known as BeiGene (Shanghai) Co., Ltd.)	PRC*	RMB1,434,344,310	100%	Medical and pharmaceutical research and development, PRC
BeOne Pharmaceutical (Suzhou) Co., Ltd. (formerly known as BeiGene (Suzhou) Co., Ltd.)	PRC*	RMB4,673,218,389	100%	Medical and pharmaceutical research and manufacturing and commercial, PRC
BeOne Medicines (Shanghai) Research & Development Co., Ltd. (formerly known as BeiGene (Shanghai) Research & Development Co., Ltd.)	PRC*	RMB620,000,000	100%	Medical and pharmaceutical research, PRC
BeOne Medicines USA, Inc. (formerly known as BeiGene USA, Inc.)	Delaware, United States	USD1	100%	Medical, pharmaceutical research and development and commercial, U.S.
BeOne Medicines AUS Pty Ltd (formerly known as BeiGene AUS Pty Ltd)	Australia	USD56,947,230	100%	Medical, pharmaceutical research and development and commercial, Australia
BeOne Medicines I GmbH (formerly known as BeiGene Switzerland GmbH)	Switzerland	CHF20,000	100%	Medical, pharmaceutical research and development and commercial, Switzerland
BeOne Medicines Hopewell Urban Renewal, LLC (formerly known as BeiGene Hopewell Urban Renewal, LLC)	New Jersey, United States	USD683,693,128	100%	Medical and pharmaceutical research and development and manufacturing. U.S.

* Limited liability company established in PRC

Basis of presentation and consolidation

The accompanying condensed consolidated balance sheet as of June 30, 2025, the condensed consolidated statements of operations and comprehensive loss for the six months ended June 30, 2025 and 2024, the condensed consolidated statements of cash flows for the six months ended June 30, 2025 and 2024, and the condensed consolidated statements of shareholders' equity for the six months ended June 30, 2025 and 2024, and the related footnote disclosures are unaudited. The accompanying unaudited interim condensed consolidated financial statements were prepared in accordance with U.S. GAAP, including guidance with respect to interim financial information and in conformity with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for annual financial statements. These financial statements should be read in conjunction with the consolidated financial statements and related footnotes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 (the "Annual Report").

The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all normal recurring adjustments, necessary to present a fair statement of the results for the interim periods presented. Results of operations for the six months ended June 30, 2025 are not necessarily indicative of the results expected for the full fiscal year or for any future annual or interim period.

The unaudited interim condensed consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany transactions and balances between the Company and its subsidiaries are eliminated upon consolidation.

Use of estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Areas where management uses subjective judgment include, but are not limited to, estimating the useful lives of long-lived assets, estimating variable consideration in product sales and collaboration revenue arrangements, identifying separate performance obligations and the standalone selling price of each performance obligation in the Company's revenue arrangements, assessing the impairment of long-lived assets, valuation and recognition of share-based compensation expenses, realizability of deferred tax assets, estimating uncertain tax positions, valuation of inventory, estimating the allowance for credit losses, determining defined benefit pension plan obligations, measurement of right-of-use assets and lease liabilities, and the fair value of financial instruments. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities and reported amounts of revenues and expenses. Actual results could differ from these estimates.

Recent accounting pronouncements

New accounting standards which have not yet been adopted

In November 2024, the FASB issued Accounting Standards Update ("ASU") 2024-03, *Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures* (Subtopic 220-40): Disaggregation of Income Statement Expenses. This update requires that at each interim and annual reporting period public entities disclose (1) the amounts of purchases of inventory, employee compensation, depreciation, amortization, and depletion in commonly presented expense captions; (2) certain amounts that are already required to be disclosed under current U.S. GAAP in the same disclosure as the other disaggregation requirements; (3) a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively; and (4) the total amount of selling expenses and, in annual reporting periods, the definition of selling expenses. In January 2025, the FASB issued ASU 2025-01, *Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures* (Subtopic 220-40): Clarifying the Effective Date. This update clarifies that ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact on its financial statements of adopting this guidance.

In December 2023, the FASB issued ASU 2023-09, *Income Taxes* (Topic 740): Improvements to Income Tax Disclosures. This update requires that public entities on an annual basis, (1) in the rate reconciliation, disclose specific categories and provide additional information for reconciling items that meet a quantitative threshold; (2) about income taxes paid, disclose the amount of income taxes paid (net of refunds received) disaggregated by federal, state, and foreign taxes and by individual jurisdiction in which income taxes paid (net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received); and (3) disclose income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign and income tax expense (or benefit) disaggregated by federal, state, and foreign. This update is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. This guidance should be applied on a prospective basis. Retrospective application is permitted. The Company does not expect that the adoption of ASU 2023-09 will have a significant impact on the Company's consolidated financial statements as the standard does not change the recognition or measurement of current and deferred income taxes and is currently evaluating the impact on the income tax disclosures.

Significant accounting policies

For a more complete discussion of the Company's significant accounting policies and other information, the unaudited interim condensed consolidated financial statements and notes thereto should be read in conjunction with the consolidated financial statements included in the Company's Annual Report for the year ended December 31, 2024.

There have been no material changes to the Company's significant accounting policies as of and for the six months ended June 30, 2025, as compared to the significant accounting policies described in the Annual Report.

2. Fair Value Measurements

The Company measures certain financial assets and liabilities at fair value. Fair value is determined based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, as determined by either the principal market or the most advantageous market. Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy, as follows:

Level 1 – Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the asset or liability.

The Company considers an active market to be one in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis, and considers an inactive market to be one in which there are infrequent or few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers.

The following tables present the Company's financial assets and liabilities measured and recorded at fair value on a recurring basis using the above input categories as of June 30, 2025 and December 31, 2024:

As of June 30, 2025	**Quoted Price in Active Market for Identical Assets (Level 1) US$'000**	**Significant Other Observable Inputs (Level 2) US$'000**	**Significant Unobservable Inputs (Level 3) US$'000**
Cash equivalents			
Money market funds	863,314	–	–
Other non-current assets (Note 4):			
Equity securities with readily determinable fair values	218	–	–
Convertible debt instrument	–	–	8,792
Total	863,532	–	8,792

As of December 31, 2024	**Quoted Price in Active Market for Identical Assets (Level 1) US$'000**	**Significant Other Observable Inputs (Level 2) US$'000**	**Significant Unobservable Inputs (Level 3) US$'000**
Cash equivalents			
Money market funds	950,704	–	–
Prepaid expenses and other current assets:			
Convertible debt instrument	–	–	618
Other non-current assets (Note 4):			
Equity securities with readily determinable fair values	2,113	168	–
Convertible debt instrument	–	–	4,616
Total	952,817	168	5,234

The Company's cash equivalents are highly liquid investments with original maturities of 3 months or less. The Company determines the fair value of cash equivalents using a market approach based on quoted prices in active markets.

The Company's equity securities carried at fair value consist of holdings in common stock and warrants to purchase additional shares of common stock of Leap Therapeutics, Inc. ("Leap"), a publicly-traded biotechnology company. The common stock investment is measured and carried at fair value and classified as a Level 1 investment. The warrants to purchase additional shares of common stock are measured using the Black-Scholes option-pricing valuation model and classified as a Level 2 investment. Refer to Note 4, *Restricted Cash and Investments* for details of the determination of the carrying amount of private equity investments without readily determinable fair values and equity method investments.

The Company holds convertible notes issued by private biotech companies. The Company elected the fair value option method of accounting for the convertible notes. Accordingly, the convertible notes are remeasured at fair value on a recurring basis using Level 3 inputs, with any changes in the fair value option recorded in other income (expense), net. The Company recorded net gains on fair value adjustment of US$1,211,000 for the six months ended June 30, 2025, and US$138,000 for the six months ended June 30, 2024.

As of June 30, 2025 and December 31, 2024, the fair values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and short-term debt approximated their carrying values due to their short-term nature. Long-term debt approximate their fair value due to the fact that the related interest rates approximate the rates currently offered by financial institutions for similar debt instrument of comparable maturities.

3. Collaborative and Licensing Arrangements

The Company enters into collaborative arrangements for the research and development, manufacture and/or commercialization of drug products and drug candidates. To date, these collaborative arrangements have included out-licenses of and options to out-license internally developed products and drug candidates to other parties, in-licenses of products and drug candidates from other parties, and profit- and cost-sharing arrangements. These arrangements may include non-refundable upfront payments, contingent obligations for potential development, regulatory and commercial performance milestone payments, cost-sharing and reimbursement arrangements, royalty payments, and profit sharing. For detailed descriptions of each arrangement, see the Company's Annual Report for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission on February 27, 2025.

For the six months ended June 30, 2025, the Company's collaboration revenue consisted primarily of royalty revenue from Imdelltra sales outside of China under the Amgen collaboration agreement and revenue generated under the Novartis broad markets agreement. For the six months ended June 30, 2024, collaboration revenue consisted primarily of revenue generated under the Novartis broad markets agreement.

The following table summarizes total collaboration revenue recognized for the six months ended June 30, 2025 and 2024:

	Six Months Ended June 30,	
	2025	2024
Revenue from collaborators	**US$'000**	**US$'000**
Amgen royalty revenue	14,552	836
Novartis broad markets revenue	6,842	8,501
Other	579	3,417
Revenue from collaborators	21,973	12,754

In-Licensing Arrangements – Commercial

Amgen

During the six months ended June 30, 2025 and 2024, the Company recorded the following amounts related to its collaboration arrangement with Amgen. For a detailed description of the arrangement and related rights and obligations, see the Company's Annual Report for the year ended December 31, 2024 filed on February 27, 2025. The Company is still in the commercialization period for XGEVA, KYPROLIS and BLINCYTO in China.

Amounts recorded related to the Company's portion of the co-development funding on the pipeline assets for the six months ended June 30, 2025 and 2024 were as follows:

	Six Months Ended June 30,	
	2025	2024
	US$'000	US$'000
BeOne's portion of the development funding	92,715	71,005
Less: Amortization of research and development cost share liability	45,569	35,039
Research and development expense	47,146	35,966

	As of
	June 30, 2025
	US$'000
Remaining portion of development funding cap	242,916

As of June 30, 2025 and December 31, 2024, the research and development cost share liability recorded in the Company's balance sheet was as follows:

	As of	
	June 30, 2025	December 31, 2024
	US$'000	US$'000
Research and development cost share liability, current portion	108,992	111,154
Research and development cost share liability, non-current portion	10,879	54,286
Total research and development cost share liability	119,871	165,440

The total reimbursement paid under the commercial profit-sharing agreement for product sales is classified in the income statement for the six months ended June 30, 2025 and 2024 as follows:

	Six Months Ended June 30,	
	2025	2024
	US$'000	US$'000
Cost of sales – product	17,027	18,159
Research and development	(2,109)	(1,144)
Selling, general and administrative	(48,985)	(39,253)
Total	(34,067)	(22,238)

The Company purchases commercial inventory from Amgen to distribute in China. Inventory purchases amounted to US$136,032,000 during the six months ended June 30, 2025, and US$109,879,000 during the six months ended June 30, 2024. Net amounts payable to Amgen was US$110,065,000 and US$116,563,000 as of June 30, 2025 and December 31, 2024, respectively.

In-Licensing Arrangements – Development

The Company has in-licensed the rights to develop, manufacture and, if approved, commercialize multiple development stage drug candidates globally or in specific territories. These arrangements typically include non-refundable upfront payments, contingent obligations for potential development, regulatory and commercial performance milestone payments, cost-sharing arrangements, royalty payments, and profit sharing.

Upfront and milestone payments incurred under these arrangements for the six months ended June 30, 2025 and 2024 are set forth below. All upfront and development milestones were expensed to research and development expense. All regulatory and commercial milestones were capitalized as intangible assets and are being amortized over the remainder of the respective product patent or term of the commercialization agreements.

		Six Months Ended June 30,	
		2025	2024
Payments due to collaboration partners	**Classification**	**US$'000**	**US$'000**
Upfront payments	Research and development expense	500	27
Development milestones incurred	Research and development expense	–	46,500
Regulatory and commercial milestone payments	Intangible asset	20,000	–
Total		20,500	46,527

4. Restricted Cash and Investments

Restricted Cash

The Company's restricted cash primarily consists of RMB-denominated cash deposits held in designated bank accounts as collateral for letters of credit. The Company classifies restricted cash as current or non-current based on the term of the restriction. Restricted cash as of June 30, 2025 and December 31, 2024 was as follows:

	As of	
	June 30, 2025	**December 31, 2024**
	US$'000	**US$'000**
Short-term restricted cash	15,802	9,312
Long-term restricted cash	14,228	2,025
Total	30,030	11,337

In addition to the restricted cash balances above, the Company is required by the PRC securities law to use the proceeds from its offering on the STAR Market of the Shanghai Stock Exchange (the "STAR Offering") in strict compliance with the planned uses as disclosed in the PRC offering prospectus as well as those disclosed in the Company's proceeds management policy approved by the board of directors. As of June 30, 2025, the Company had cash remaining related to the STAR Offering proceeds of US$359,544,000.

Investments in Equity Securities

The following table summarizes the Company's investments in equity securities:

	As of	
	June 30, 2025 US$'000	**December 31, 2024 US$'000**
Equity securities with readily determinable fair values [1]		
Fair value of Leap common stock	218	2,113
Fair value of Leap warrants	–	168
Equity securities without readily determinable fair values		
Pi Health, Inc. [2]	40,798	40,798
Other	47,378	48,157
Equity-method investments [3]	22,289	33,081
Total	110,683	124,317

1 Represents common stock and warrants to purchase additional shares of common stock of Leap. The Company measures the investment in the common stock and warrants at fair value, with changes in fair value recorded to other income (expense), net.

2 In the first quarter of 2024, the Company divested the net assets comprising substantially all of its Pi Health business with a carrying value of US$38,063,000. The consideration received for the divestiture consisted of preferred stock in a newly formed entity, Pi Health, Inc., with a fair value of US$40,798,000 and cash consideration of US$1,000,000. The transaction resulted in a pre-tax gain of US$3,735,000 recorded within other income (expense), net during the six months ended June 30, 2024. The Company accounts for its investment as a private equity security without a readily determinable fair value, and the divestiture was not treated as a discontinued operation in the Statement of Operations and therefore the historical results of operations of the Pi Health business will remain in the Company's continuing operations.

3 In the first quarter of 2025, in connection with the wind-down of the operations and related financial obligations of one of the Company's equity-method investments, the investment's fair value was assessed to be zero. The Company recognized an other-than-temporary impairment loss of US$12,376,000 during the six months ended June 30, 2025, within unrealized losses from equity-method investments.

The following table summarizes unrealized losses related to investments in equity securities recorded in other income (expense), net for the six months ended June 30, 2025 and 2024:

	Six Months Ended June 30,	
	2025 US$'000	**2024 US$'000**
Equity securities with readily determinable fair values	(2,063)	(2,033)
Equity securities without readily determinable fair values	(3,118)	(797)
Equity-method investments	(15,274)	(4,873)

5. Accounts Receivable, net

	As of	
	June 30, 2025 US$'000	December 31, 2024 US$'000
Accounts receivable	771,720	677,270
Less: Allowance for credit losses	(944)	(992)
Total	770,776	676,278

The Company's trading terms with its customers are mainly on credit and the credit period generally ranges from 30 to 120 days. The Company seeks to maintain strict control over its outstanding receivables and overdue balances are regularly reviewed. The Company does not hold any collateral or other credit enhancements over its accounts receivable balances. Accounts receivable are non-interest-bearing. An aging analysis of the accounts receivable, based on the invoice date, is as follows:

	As of	
	June 30, 2025 US$'000	December 31, 2024 US$'000
Within 1 year	769,960	676,278
Over 1 year	816	–
Total	770,776	676,278

Changes in the allowance for credit losses related to accounts receivable consisted of the following:

	Six Months Ended June 30,	
	2025 US$'000	2024 US$'000
Beginning balance, as of December 31, 2024	992	2,026
Provision/(Reversal) for expected credit losses	53	(1,214)
Written-off	(43)	(1)
Exchange rate changes	(58)	40
Ending balance, as of June 30, 2025	944	851

6. Inventories, Net

The Company's inventories, net consisted of the following:

	As of	
	June 30, 2025 US$'000	December 31, 2024 US$'000
Raw materials	180,969	170,584
Work in process	98,922	60,118
Finished goods	222,976	264,284
Total inventories, net	502,867	494,986

7. Property, Plant and Equipment, Net

Property, plant and equipment, net are recorded at cost and consisted of the following:

	As of	
	June 30, 2025 US$'000	December 31, 2024 US$'000
Land	71,434	65,485
Building	932,950	607,857
Manufacturing equipment	258,737	244,255
Laboratory equipment	270,224	240,885
Leasehold improvement	74,476	64,680
Software, electronics and office equipment	107,340	100,348
Property, plant and equipment, at cost	1,715,161	1,323,510
Less: accumulated depreciation	(453,031)	(399,105)
Construction in progress	353,662	654,018
Property, plant and equipment, net	1,615,792	1,578,423

The Company has made a significant investment in its newly opened manufacturing and R&D center in Hopewell, New Jersey. In the six months ended June 30, 2025, US$334,635,000 of assets were placed into service. As of June 30, 2025, the Company had construction in progress of US$189,674,000 related to the Hopewell facility, the majority of which will be put into service in 2025.

Depreciation expense was US$61,468,000 for the six months ended June 30, 2025, and US$47,864,000 for the six months ended June 30, 2024.

8. Intangible Assets

Intangible assets as of June 30, 2025 and December 31, 2024 are summarized as follows:

	As of					
	June 30, 2025			December 31, 2024		
	Gross carrying amount US$'000	Accumulated amortization US$'000	Intangible assets, net US$'000	Gross carrying amount US$'000	Accumulated amortization US$'000	Intangible assets, net US$'000
Finite-lived intangible assets:						
Developed products	76,294	(11,953)	64,341	62,889	(12,370)	50,519
Other	8,987	(8,438)	549	8,987	(8,411)	576
Total finite-lived intangible assets	85,281	(20,391)	64,890	71,876	(20,781)	51,095

Developed products represent post-approval milestone payments under license and commercialization agreements. The Company is amortizing the developed products over the remainder of the respective product patent or the term of the commercialization agreements.

Amortization expense for developed products is included in cost of sales – product in the accompanying consolidated statements of operations. Amortization expense for other intangible assets is included in selling, general and administrative expense in the accompanying consolidated statements of operations.

The weighted-average life for each finite-lived intangible assets is approximately 11 years. Amortization expense was as follows:

	Six Months Ended June 30,	
	2025	2024
	US$'000	US$'000
Amortization expense – Cost of sales – product	6,922	2,360
Amortization expense – Selling, general and administrative	28	–
Total	6,950	2,360

As of June 30, 2025, estimated amortization expense for each of the five succeeding years and thereafter was as follows:

Year Ending December 31,	Cost of Sales – Product US$'000	Selling, General and Administrative US$'000	Total US$'000
2025 (remainder of year)	3,082	39	3,121
2026	6,164	67	6,231
2027	6,164	67	6,231
2028	6,164	67	6,231
2029	6,164	67	6,231
2030 and thereafter	36,603	242	36,845
Total	64,341	549	64,890

9. Income Taxes

Income tax expense was US$24,859,000 for the six months ended June 30, 2025 and US$22,209,000 for the six months ended June 30, 2024. The income tax expense for the six months ended June 30, 2025 was primarily attributable to current Switzerland tax expense based on year to date earnings, current China tax expense due to certain non-deductible expenses, offset with a net U.S. tax benefit mainly driven by changes to the Company's estimate of U.S. R&D credits to be taken for prior periods and are reflected as a discrete item in Q2 2025. The income tax expense for the six months ended June 30, 2024 was primarily attributable to current U.S. tax expense determined after other special tax deductions and research and development tax credits, current Switzerland tax expense based on year to date earnings, and current China tax expense due to certain non-deductible expenses.

On a quarterly basis, the Company evaluates the realizability of deferred tax assets by jurisdiction and assesses the need for a valuation allowance. In assessing the realizability of deferred tax assets, the Company considers historical profitability, evaluation of scheduled reversals of deferred tax liabilities, projected future taxable income and tax-planning strategies. Valuation allowances have been provided on deferred tax assets where, based on all available evidence, it was considered more likely than not that some portion or all of the recorded deferred tax assets will not be realized in future periods. After consideration of all positive and negative evidence, as of June 30, 2025, the Company will maintain a full valuation allowance against its net deferred tax assets.

As of June 30, 2025, the Company had gross unrecognized tax benefits of US$21,488,000. The Company does not anticipate that the amount of existing unrecognized tax benefits will significantly change within the next 12 months. The Company's reserve for uncertain tax positions increased by US$4,249,000 in the six months ended June 30, 2025, primarily due to U.S. federal and state tax credits and incentives.

10. Supplemental Balance Sheet Information

Prepaid expenses and other current assets consist of the following:

	As of	
	June 30, 2025 US$'000	December 31, 2024 US$'000
Prepaid research and development costs	76,231	64,277
Payroll tax receivable	69,987	14,569
Other receivables	39,367	18,259
Prepaid taxes	27,058	23,792
Prepaid general and administrative expenses	16,967	21,253
Short-term restricted cash	15,802	9,312
Prepaid insurance	8,486	6,242
Prepaid manufacturing cost	6,157	19,333
Other current assets	20,467	15,882
Total	280,522	192,919

Other non-current assets consist of the following:

	As of	
	June 30, 2025 US$'000	December 31, 2024 US$'000
Long-term investments	119,475	128,933
Long-term restricted cash	14,228	2,025
Prepaid supply cost	12,321	12,249
Rental deposits and other	7,733	8,481
Prepayment of property and equipment	4,847	5,927
Prepaid VAT	3,118	2,875
Total	161,722	160,490

Accrued expenses and other payables consist of the following:

	As of	
	June 30, 2025 US$'000	December 31, 2024 US$'000
Revenue rebates and returns related	297,317	235,600
Compensation related	233,246	248,348
Individual income tax and other taxes	109,376	34,904
External research and development activities related	106,185	154,269
Commercial activities	99,749	77,530
Accrued general and administrative expenses	46,091	31,106
Other	16,918	21,956
Total	908,882	803,713

Other long-term liabilities consist of the following:

	As of	
	June 30, 2025 US$'000	December 31, 2024 US$'000
Deferred government grant income	29,569	30,324
Pension liability	17,329	16,405
Asset retirement obligation	3,573	3,794
Other	12,608	16,212
Total	63,079	66,735

11. Accounts Payable

An aging analysis of the accounts payable as of the end of the reporting period, based on the invoice date, is as follows:

	As of	
	June 30, 2025 US$'000	December 31, 2024 US$'000
Within 1 year	360,371	404,738
Over 1 year	412	259
Total	360,783	404,997

The accounts payable are non-interest-bearing and repayable within the normal operating cycle or on demand.

12. Debt

The following table summarizes the Company's short-term and long-term debt obligations as of June 30, 2025 and December 31, 2024:

Lender	Borrower	Term	Maturity Date	Note	As of June 30, 2025 US$'000	As of December 31, 2024 US$'000
China Construction Bank	BeOne Guangzhou Biologics Manufacturing Co., Ltd.	9-year	June 11, 2027	1	18,845	16,440
China Merchants Bank	BeOne Guangzhou Biologics Manufacturing Co., Ltd.	9-year	January 20, 2029	2	8,774	8,611
China Merchants Bank	BeOne Guangzhou Biologics Manufacturing Co., Ltd.	9-year	November 8, 2029	3	8,294	8,148
China CITIC Bank	BeOne Pharmaceutical (Suzhou) Co., Ltd.	10-year	July 28, 2032	4	5,947	1,384
China Merchants Bank	BeOne Medicines Ltd.	1-year	January 21, 2026	5	380,000	380,000
China Minsheng Bank	BeOne Medicines Ltd.	1-year	December 16, 2025	6	150,000	150,000
China Industrial Bank	BeOne Medicines USA, Inc.	364-day	June 28, 2026	7	94,223	–
China Industrial Bank	BeOne Medicines Ltd.	364-day	March 27, 2025	8	–	92,475
China Merchants Bank	BeOne Guangzhou Biologics Manufacturing Co., Ltd.	1-year	June 5, 2025	9	–	54,800
HSBC Bank	BeOne Medicines Ltd.	1-year	June 17, 2026	10	47,461	46,580
Shanghai Pudong Development Bank	BeOne Medicines Ltd.	1-year	November 24, 2025	11	94,850	93,091
Total short-term debt					808,394	851,529

Lender	Borrower	Term	Maturity Date	Note	As of June 30, 2025 US$'000	As of December 31, 2024 US$'000
China Construction Bank	BeOne Guangzhou Biologics Manufacturing Co., Ltd.	9-year	June 11, 2027	1	31,408	41,100
China Merchants Bank	BeOne Guangzhou Biologics Manufacturing Co., Ltd.	9-year	January 20, 2029	2	24,129	27,987
China Merchants Bank	BeOne Guangzhou Biologics Manufacturing Co., Ltd.	9-year	November 8, 2029	3	29,497	33,020
China CITIC Bank	BeOne Pharmaceutical (Suzhou) Co., Ltd.	10-year	July 28, 2032	4	61,057	64,377
Total long-term debt					146,091	166,484

1 The credit facility offers a borrowing capacity of RMB580,000,000, denominated in RMB, and bears floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 3.8% as of June 30, 2025. The outstanding principal balance is payable in semi-annual installments. The Company repaid US$8,358,000 (RMB60,000,000) during the six months ended June 30, 2025. The loan is secured by BeOne Guangzhou Biologics Manufacturing Co., Ltd.'s property ownership certificate and fixed assets.

2 The credit facility offers a borrowing capacity of RMB350,000,000, denominated in RMB, and bears floating interest rates benchmarking against prevailing interest rates of financial institutions in the PRC. The loan interest rate was 3.4% as of June 30, 2025. The outstanding principal balance is payable in quarterly installments. The Company repaid US$4,323,000 (RMB31,429,000) during the six months ended June 30, 2025. The loan is secured by Guangzhou Factory's second land use right and certain fixed assets.

3 The credit facility offers a borrowing capacity of RMB378,000,000, denominated in RMB, and bears floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 3.3% as of June 30, 2025. The outstanding principal balance is payable in quarterly installments. The Company repaid US$4,118,000 (RMB29,765,000) during the six months ended June 30, 2025. The loan is secured by fixed assets placed into service in the third phase of the Guangzhou manufacturing facility's buildout.

4 The credit facility offers a borrowing capacity of RMB480,000,000, denominated in RMB, and bears floating interest rate benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 3.4% as of June 30, 2025. The outstanding principal balance is payable in semi-annual installments. The loan is secured by BeOne Pharmaceutical (Suzhou) Co., Ltd.'s property ownership certificate of the small molecule manufacturing campus in Suzhou, China.

5 The working capital loan facility offers a borrowing capacity of up to US$380,000,000, denominated in USD, and bears floating interest rates benchmarking the secured overnight financing rate. The loan interest rate was 6.2% as of June 30, 2025. US$300,000,000 of the borrowings matures on December 17, 2025, and US$80,000,000 matures on January 21, 2026.

6 The working capital loan facility offers a borrowing capacity of up to US$150,000,000, denominated in USD. The loan interest rate was 6.8% as of June 30, 2025.

7 The working capital loan facility offers a borrowing capacity of up to RMB675,000,000, denominated in RMB. The loan interest rate was 3.0% as of June 30, 2025.

8 The working capital loan facility offered a borrowing capacity of up to RMB675,000,000, denominated in RMB. The Company repaid the principal during the six months ended June 30, 2025.

9 The working capital loan facility offers a borrowing capacity of up to of RMB400,000,000, denominated in RMB. The Company repaid the principal during the six months ended June 30, 2025.

10 The working capital loan facility offers a borrowing capacity of up to RMB340,000,000, denominated in RMB, and bears floating interest rates benchmarking Hong Kong interbank market rate for RMB. The loan interest rate was 5.2% as of June 30, 2025.

11 The working capital loan facility offers a borrowing capacity of up to RMB700,000,000, denominated in RMB. The loan interest rate was 2.9% as of June 30, 2025.

The Company has numerous financial and non-financial covenants on its debt obligations with various banks and other lenders. Some of these covenants include default and/or cross-default provisions that could require acceleration of repayment of loans in the event of default. However, the Company's debt is primarily short-term in nature. Any acceleration would be a matter of months but may impact the Company's ability to refinance debt obligations if an event of default occurs. As of June 30, 2025, the Company was in compliance with all covenants of its material debt agreements.

Interest Expense

Interest expense recognized for the six months ended June 30, 2025 was US$25,009,000, among which, US$10,013,000 was capitalized. Interest expense recognized for the six months ended June 30, 2024 was US$25,637,000, among which, US$17,521,000 was capitalized. Interest paid for the six months ended June 30, 2025 and 2024, net of amounts capitalized, amounted to US$14,006,000 and US$6,628,000, respectively.

13. Product Revenue

The Company's product revenue is primarily derived from the sale of its internally developed products BRUKINSA® and TEVIMBRA® in the U.S., China, EU, and other regions; XGEVA®, BLINCYTO® and KYPROLIS® in China under a license from Amgen; and POBEVCY® in China under a license from Bio-Thera.

The table below presents the Company's net product revenue for the six months ended June 30, 2025 and 2024.

	Six Months Ended June 30,	
	2025	**2024**
	US$'000	**US$'000**
Product revenue – gross	3,057,904	2,111,619
Less: Rebates and sales returns	(647,298)	(443,555)
Product revenue – net	2,410,606	1,668,064

The following table disaggregates net product revenue by product for the six months ended June 30, 2025 and 2024:

	Six Months Ended June 30,	
	2025	**2024**
	US$'000	**US$'000**
BRUKINSA®	1,741,504	1,125,914
TEVIMBRA®	364,688	303,687
XGEVA®	151,741	98,435
BLINCYTO®	49,493	33,497
KYPROLIS®	39,144	30,047
POBEVCY®	24,987	28,205
Other	39,049	48,279
Total product revenue – net	2,410,606	1,668,064

The following table presents the roll-forward of accrued revenue rebates and returns for the six months ended June 30, 2025 and 2024:

	Rebates, Returns and Other Deductions US$'000	Contra AR Accruals US$'000	Total US$'000
Balance at December 31, 2024	235,600	50,699	286,299
Accrual	283,525	363,773	647,298
Payments	(221,808)	(361,633)	(583,441)
Balance at June 30, 2025	297,317	52,839	350,156
Balance at December 31, 2023	139,936	30,435	170,371
Accrual	222,179	221,376	443,555
Payments	(188,852)	(209,450)	(398,302)
Balance at June 30, 2024	173,263	42,361	215,624

14. Income (Loss) before Income Taxes

The Company's income (loss) before income taxes is arrived at after charging/(crediting):

	Note	Six Months Ended June 30, 2025 US$'000	2024 US$'000
Cost of inventories sold		329,608	263,067
Depreciation of property, plant and equipment		61,468	47,970
Research and development costs (note)		1,006,783	915,104
Operating lease cost		12,540	13,235
Amortization of license rights	8	6,950	2,360
Employee benefit expense (including directors' and chief executive's remuneration):			
Wages, salaries and other benefits		704,137	633,187
Share-based compensation expenses	16	246,004	219,408
Pension scheme contributions (defined contribution scheme)		44,641	39,220
		994,782	891,815
Gain on deconsolidation of entity		–	(3,735)
Foreign exchange differences, net		(6,502)	13,523
Expected credit losses	5	53	(1,214)
Impairment of inventories		8,485	2,484
Bank interest income		(24,342)	(38,145)

Note:

During the six months ended June 30, 2025 and 2024, research and development costs of approximately US$432,686,000 and US$384,854,000 were also included in employee benefit expense.

15. Earnings (Loss) Per Share/ADS

The following table reconciles the numerator and denominator in the computations of earnings (loss) per share/ADS:

	Six Months Ended June 30,	
	2025	2024
	US$'000	US$'000
Numerator:		
Net income (loss)	95,590	(371,555)
Denominator:		
Weighted-average shares outstanding – basic	1,399,159,898	1,358,315,145
Dilutive common share equivalents	55,136,577	–
Weighted-average shares outstanding – diluted	1,454,296,475	1,358,315,145
Anti-dilutive common share equivalents excluded from above	1,496,899	–
Earnings (loss) per share (in US$):		
Basic	0.07	(0.27)
Diluted	0.07	(0.27)
Earnings (loss) per ADS (in US$):		
Basic	0.89	(3.56)
Diluted	0.85	(3.56)

For the six months ended June 30, 2025, diluted earnings per share was computed using the weighted-average number of ordinary shares and the effect of potentially dilutive shares outstanding during the periods. Potentially dilutive shares consist of stock options, restricted stock units and ESPP shares. The dilutive effect of outstanding stock options, restricted stock units and ESPP shares is reflected in diluted net earnings per share using the treasury stock method.

For the six months ended June 30, 2024, the Company was in a net loss position and the effects of all share options, restricted share units and ESPP shares were excluded from the calculation of diluted loss per share, as their effect would have been anti-dilutive.

Each ADS represents 13 ordinary shares. Basic and diluted earnings (loss) per ADS was derived from the basic and diluted earnings (loss) per share, respectively.

16. Share-Based Compensation Expense

Share Option, Restricted Share Units and Performance Share Units

During the six months ended June 30, 2025, the Company granted options for 2,527,499 ordinary shares, restricted share units for 26,510,263 ordinary shares, and performance share units for 1,837,901 ordinary shares under the Company's share option and incentive plan. As of June 30, 2025, options, restricted share units, and performance share units for ordinary shares outstanding totaled 56,870,418, 82,357,691, and 3,896,477, respectively. As of June 30, 2025, share-based awards to acquire 58,818,941 ordinary shares were available for future grant under the Company's share option and incentive plan.

Employee Share Purchase Plan

The Company's employee share purchase plan (the "ESPP") allows eligible employees to purchase the Company's ordinary shares (including in the form of ADSs) at the end of each offering period, which will generally be six months, at a 15% discount to the market price of the Company's ADSs at the beginning or the end of each offering period, whichever is lower, using funds deducted from their payroll during the offering period. Eligible employees are able to authorize payroll deductions of up to 10% of their eligible earnings, subject to applicable limitations.

As of June 30, 2025, 3,998,286 ordinary shares were available for future issuance under the ESPP.

The following table summarizes the shares issued under the ESPP:

Issuance Date	Number of Ordinary Shares Issued	Market Price[1]		Purchase Price[2]		Proceeds
		ADS US$	Ordinary US$	ADS US$	Ordinary US$	US$'000
February 28, 2025	955,396	188.26	14.48	160.02	12.31	11,760
August 31, 2024	1,035,996	165.02	12.69	140.27	10.78	11,178
February 29, 2024	1,021,397	165.65	12.74	140.80	10.83	11,063

1 The market price is the lower of the closing price on the Nasdaq Stock Market on the issuance date or the offering date, in accordance with the terms of the ESPP.

2 The purchase price is the price which was discounted from the applicable market price, in accordance with the terms of the ESPP.

Share-Based Compensation Expense

The following table summarizes total share-based compensation expense recognized for the six months ended June 30, 2025 and 2024:

	Six Months Ended June 30,	
	2025 US$'000	2024 US$'000
Research and development	106,159	93,451
Selling, general and administrative	139,845	125,957
Total	246,004	219,408

17. Accumulated Other Comprehensive Loss

The movement of accumulated other comprehensive loss was as follows:

	Foreign Currency Translation Adjustments US$'000	Pension Liability Adjustments US$'000	Total US$'000
Balance as of December 31, 2024	(135,552)	(13,436)	(148,988)
Other comprehensive income before reclassifications	34,988	(205)	34,783
Amounts reclassified from accumulated other comprehensive loss	–	507	507
Net-current period other comprehensive income	34,988	302	35,290
Balance as of June 30, 2025	(100,564)	(13,134)	(113,698)

18. Restricted Net Assets

The Company's ability to pay dividends may depend on the Company receiving distributions of funds from its PRC subsidiaries. Relevant PRC statutory laws and regulations permit payments of dividends by the Company's PRC subsidiaries only out of the subsidiary's retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. The results of operations reflected in the condensed consolidated financial statements prepared in accordance with GAAP differ from those reflected in the statutory financial statements of the Company's PRC subsidiaries.

In accordance with the company law of the PRC, a domestic enterprise is required to provide statutory reserves of at least 10% of its annual after-tax profit until such reserve has reached 50% of its respective registered capital based on the enterprise's PRC statutory accounts. A domestic enterprise is also required to provide discretionary surplus reserve, at the discretion of the board of directors, from the profits determined in accordance with the enterprise's PRC statutory accounts. The aforementioned reserves can only be used for specific purposes and are not distributable as cash dividends. The Company's PRC subsidiaries were established as domestic enterprises and therefore are subject to the above-mentioned restrictions on distributable profits.

As a result of these PRC laws and regulations, including the requirement to make annual appropriations of at least 10% of after-tax income and set aside as general reserve fund prior to payment of dividends, the Company's PRC subsidiaries are restricted in their ability to transfer a portion of their net assets to the Company.

Foreign exchange and other regulations in the PRC may further restrict the Company's PRC subsidiaries from transferring funds to the Company in the form of dividends, loans and advances. As of June 30, 2025 and December 31, 2024, amounts restricted were the net assets of the Company's PRC subsidiaries, which, after intercompany eliminations, amounted to US$1,915,949,000 and US$1,709,961,000, respectively.

19. Commitments and Contingencies

Purchase Commitments

As of June 30, 2025, the Company had non-cancellable purchase commitments amounting to US$130,087,000, of which US$32,591,000 related to minimum purchase requirements for supply purchased from contract manufacturing organizations and US$97,496,000 related to binding purchase obligations of inventory from Amgen. The Company does not have any minimum purchase requirements for inventory from Amgen.

Capital Commitments

The Company had capital commitments amounting to US$62,029,000 for the acquisition of property, plant and equipment as of June 30, 2025, related to various facilities across the globe, including the manufacturing and clinical R&D campus in Hopewell, New Jersey.

Co-Development Funding Commitment

Under the Amgen Collaboration Agreement, the Company is responsible for co-funding global development costs for the Amgen oncology pipeline assets up to a total cap of US$1,250,000,000. The Company is funding its portion of the co-development costs by contributing cash and/or development services. As of June 30, 2025, the Company's remaining co-development funding commitment was US$242,916,000.

Funding Commitment

The Company had committed capital related to equity investments in the amount of US$15,890,000. As of June 30, 2025, the remaining capital commitment was US$6,740,000 and is expected to be paid from time to time over the investment period.

20. Related Party Transactions

(a) In addition to the transactions detailed elsewhere in this financial information, the Company had the following related party transactions for the six months ended June 30, 2025 and 2024:

Xiaodong Wang, Chairman of Scientific Advisory Board, director and shareholder, provided consulting service to the Company, and the compensation received by Dr. Wang for consulting service for the six months ended June 30, 2025 and 2024 consisted of (i) US$50,000 (2024: US$50,000) in consulting fees, (ii) US$75,000 (2024: US$75,000) as a performance-based cash bonus, (iii) share-based compensation expenses for options and RSUs of US$2,201,000 (2024: US$2,099,000).

(b) Compensation of key management personnel of the Company:

	Six Months Ended June 30,	
	2025	**2024**
	US$'000	**US$'000**
Short term employee benefits	4,494	3,786
Post-employment benefits	62	75
Share-based compensation expenses	20,575	21,106
Total compensation paid to key management personnel	25,131	24,967

21. Segment and Geographic Information

The Company operates in one segment: pharmaceutical products. Its chief operating decision maker is the Chief Executive Officer, who makes operating decisions, assesses performance and allocates resources on a consolidated basis.

The primary measure of segment profitability for the Company's operating segment is considered to be consolidated net income (loss). Significant segment expenses reviewed by the CODM on a regular basis included within net income (loss) include cost of product sales, research and development expenses and selling, general and administrative expenses which are separately presented on the Company's consolidated statements of operations. Other segment items within net income (loss) include interest income, net, other income (expense), net and income tax expense.

The Company's long-lived assets are primarily located in the U.S. and China.

Net product revenues by geographic area are based upon the location of the customer, and net collaboration revenue is recorded in the jurisdiction in which the related income is expected to be sourced from. Total revenues by geographic area are presented as follows:

	Six Months Ended June 30,	
	2025	2024
	US$'000	US$'000
U.S. - total revenue	**1,261,638**	**832,886**
Product revenue	1,248,743	830,821
Collaboration revenue	12,895	2,065
China – total revenue	**832,516**	**672,446**
Product revenue	825,164	662,774
Collaboration revenue	7,352	9,672
Europe – total revenue	**270,938**	**149,249**
Product revenue	269,212	148,232
Collaboration revenue	1,726	1,017
Rest of world – total revenue	**67,487**	**26,237**
Product revenue	67,487	26,237
Total Revenue	**2,432,579**	**1,680,818**

22. Reconciliation between U.S. GAAP and international financial reporting standards

The unaudited interim condensed consolidated financial statements are prepared in accordance with U.S. GAAP, which differ in certain respects from International Financial Reporting Standards ("IFRS"). The effects of material differences between the financial information of the Company prepared under U.S. GAAP and IFRS are as follows:

	Six months ended June 30, 2025				
	Amounts as reported under U.S. GAAP	IFRS adjustments			Amounts under IFRS
		Share-based compensation (note (i))	Income taxes in the interim period (note (iii))	Lease (note (iv))	
Consolidated statement of operations data	**US$'000**	**US$'000**	**US$'000**	**US$'000**	**US$'000**
Research and development	(1,006,783)	(4,198)	–	620	(1,010,361)
Selling, general and administrative	(997,201)	(3,438)	–	826	(999,813)
Interest income, net	9,345	–	–	(1,744)	7,601
Income before income tax expense	120,449	(7,636)	–	(298)	112,515
Income tax expense	(24,859)	–	(23,201)	–	(48,060)
Net income	95,590	(7,636)	(23,201)	(298)	64,455

	Six months ended June 30, 2024				
	Amounts as reported under U.S. GAAP	IFRS adjustments			Amounts under IFRS
		Share-based compensation (note (i))	Income taxes in the interim period (note (iii))	Lease (note (iv))	
Consolidated statement of operations data	**US$'000**	**US$'000**	**US$'000**	**US$'000**	**US$'000**
Research and development	(915,104)	(10,395)	–	811	(924,688)
Selling, general and administrative	(871,156)	(12,922)	–	1,000	(883,078)
Interest income, net	29,385	–	–	(1,286)	28,099
Loss before income tax expense	(349,346)	(23,317)	–	525	(372,138)
Income tax expense	(22,209)	–	(2,951)	–	(25,160)
Net loss	(371,555)	(23,317)	(2,951)	525	(397,298)

	As of June 30, 2025					
	Amounts as reported under U.S. GAAP	IFRS adjustments				Amounts under IFRS
Consolidated balance sheet data	US$'000	Share-based compensation (note (i)) US$'000	Preferred Shares (note (ii)) US$'000	Income taxes in the interim period (note (iii)) US$'000	Lease (note (iv)) US$'000	US$'000
Prepaid expenses and other current assets	280,522	–	–	(23,201)	–	257,321
Operating lease right-of-use assets	145,769	–	–	–	(2,207)	143,562
Total assets	6,298,394	–	–	(23,201)	(2,207)	6,272,986
Additional paid-in capital	12,395,276	7,636 317,575*	– 307,894*	– –	– –	13,028,381
Accumulated deficit	(8,511,246)	(7,636) (317,575)*	– (307,894)*	(23,201) –	(298) (1,909)*	(9,169,759)
Total equity	3,770,475	–	–	(23,201)	(2,207)	3,745,067

	As of December 31, 2024				
	Amounts as reported under U.S. GAAP	IFRS adjustments			Amounts under IFRS
Consolidated balance sheet data	US$'000	Share-based compensation (note (i)) US$'000	Preferred Shares (note (ii)) US$'000	Lease (note (iv)) US$'000	US$'000
Operating lease right-of-use assets	139,309	–	–	(1,909)	137,400
Total assets	5,920,910	–	–	(1,909)	5,919,001
Additional paid-in capital	12,087,908	40,846 276,729*	– 307,894*	– –	12,713,377
Accumulated deficit	(8,606,836)	(40,846) (276,729)*	– (307,894)*	475 (2,384)*	(9,234,214)
Total equity	3,332,222	–	–	(1,909)	3,330,313

* IFRS adjustments brought forward from prior years.

Notes:

(i) Share based compensation

Under U.S. GAAP, the Company has elected to recognize compensation expense using the straight-line method for all employee equity awards granted with graded vesting based on service conditions provided that the amount of compensation cost recognized at any date is at least equal to the portion of the grant date value of the options that are vested at that date.

Under IFRS, the accelerated method is required to recognize compensation expense for all employee equity awards granted with graded vesting.

A difference of US$7,636,000 arose between the amount of share-based compensation (included in research and development expenses, and selling, general and administrative expenses) recognized under U.S. GAAP and IFRS for the six months ended June 30, 2025 (six months ended June 30, 2024: US$23,317,000).

(ii) Preferred Shares

Prior to the Company's U.S. IPO, the Company had preferred shares, which were converted into ordinary shares at the time of the U.S. IPO. Under U.S. GAAP, the preferred shares issued by the Company were classified as mezzanine equity, as these convertible preferred shares were redeemable upon the occurrence of a conditional event (i.e., Liquidation Transaction). The holders of the preferred shares had a liquidation preference upon the occurrence of the conditional event. The conversion options and contingent redemption options of the convertible preferred shares do not qualify for bifurcation accounting because the conversion options are clearly and closely related to the host instrument and the underlying ordinary shares of the conversion options and redemption options are not publicly traded nor readily convertible into cash. No beneficial conversion features are recognized for the convertible preferred shares, as the fair values per ordinary share at the respective commitment dates were less than the most favorable conversion prices. The Company concluded that the preferred shares were not redeemable currently and it was not probable that the preferred shares would become redeemable because the likelihood of the Liquidation Transaction was remote. Therefore, no adjustment will be made to the initial carrying amount of the Preferred Shares until it is probable that they will become redeemable.

Under IFRS, the preferred shares were regarded as a hybrid instrument consisting of a host debt instrument and a conversion option as a derivative. This was the result of certain redemption triggering events of the preferred shares being outside the control of the ordinary shareholders of the Company. In addition, the holders of the preferred shares were entitled to convert the preferred shares into a variable number of the Company's ordinary shares upon occurrence of certain anti-dilution events. Under IFRS, the Company initially recorded all of the preferred shares as financial liabilities at fair value, with subsequent changes in the amount of the fair value of the preferred shares recognized in the statement of operations in the year in which they arose. Hence, all the fair value changes in the preferred shares of US$307,894,000 prior to the conversion into the Company's ordinary shares in February 2016 was recognized in the statement of operations under IFRS, and the cumulative effect of such fair value changes was recognized in the additional paid in capital account upon the conversion of the preferred shares into the ordinary shares. The effect of such IFRS adjustments on accumulated deficit and additional paid-in capital was US$307,894,000, which was all carried forward to opening balance sheets of subsequent financial years/periods.

(iii) Income taxes in the interim period

Under U.S. GAAP, the interim tax provision is determined by applying the estimated annual worldwide effective tax rate for the consolidated entity to the worldwide consolidated year-to-date pretax income.

Under IFRS, the interim tax provision is determined by applying an estimated average annual effective tax rate to interim period pretax income. A separate estimated average annual effective tax rate is determined for each material tax jurisdiction and applied individually to the interim period pretax income of each jurisdiction.

(iv) Lease

As a lessee, the Company recognized a lease liability based on the present value of the total remaining lease payments, and a corresponding right of use asset under U.S. GAAP. The Company subsequently recognize an operating lease expense on straight line basis over the lease term.

IFRS 16, Lease requires entities to present interest expense on the lease liability and depreciation on the right of use assets separately in the statement of operations. This will change the allocation of expenses and the total amount of expenses recognized for each period of the lease term. The combination of a straight-line depreciation of the right-of-use asset and the effective interest rate method applied to the lease liability will result in a higher total charge to profit or loss in the initial years of the lease terms, and a decreasing expense during the latter years of the lease terms.

23. Dividends

The board of directors of the Company did not recommend the distribution of any interim dividend for the six months ended June 30, 2025 (six months ended June 30, 2024: nil).

MANAGEMENT DISCUSSION AND ANALYSIS

Non-GAAP Financial Measures

We provide certain financial measures that are not defined under U.S. GAAP, commonly referred to as non-GAAP financial measures, including Adjusted Operating Expenses and Adjusted Income (Loss) from Operations and certain other non-GAAP measures, each of which include adjustments to GAAP figures. These non-GAAP measures are intended to provide additional information on our operating performance. Adjustments to our GAAP figures exclude, as applicable, non-cash items such as share-based compensation, depreciation and amortization. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. We maintain an established non-GAAP policy that guides the determination of what items may be excluded in non-GAAP financial measures. We believe that these non-GAAP measures, when considered together with the GAAP figures, can enhance an overall understanding of our operating performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of our historical and expected financial results and trends and to facilitate comparisons between periods and with respect to projected information. In addition, these non-GAAP financial measures are among the indicators BeOne's management uses for planning and forecasting purposes and measuring our performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, GAAP financial measures. The non-GAAP financial measures used by BeOne may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies.

Overview

Our second quarter performance reinforces us as a global oncology leader and proves our ability to deliver sustainable, long-term growth. BRUKINSA continues as the BTK inhibitor market leader in the US across five indications. Our two additional Phase 3 hematology assets, BCL2 inhibitor sonrotoclax and BTK CDAC BGB-16673, have the potential to expand our franchise with pivotal data readouts and new trial initiations anticipated in the near-term. At our recent Investor R&D Day, we outlined more than 20 expected R&D milestones in the next 18 months. This includes advances across our solid tumor pipeline, where we are building future global franchises targeting a range of highly prevalent cancers.

Recent Business Developments

On July 31, 2025, we announced that the European Medicines Agency ("EMA") has granted PRIority MEdicines (PRIME) designation to the Company's investigational Bruton's tyrosine kinase (BTK) degrader, BGB-16673, for the treatment of patients with Waldenstrom's macroglobulinemia (WM) previously treated with a BTK inhibitor.

On July 28, 2025, we announced that the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA® (tislelizumab), in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment, for the treatment of adult patients with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence.

On July 10, 2025, we announced that the European Commission has approved TEVIMBRA, in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with metastatic or recurrent nasopharyngeal carcinoma, not amenable to curative surgery or radiotherapy.

On June 26, 2025, we announced major advancements to our industry-leading oncology pipeline during our investor R&D Day.

On June 25, 2025, we announced that the CHMP of the European Medicines Agency issued a positive opinion recommending approval of a new film-coated tablet formulation of BRUKINSA® (zanubrutinib) for all approved indications. The CHMP positive opinion will now be reviewed by the European Commission, which will grant the marketing authorization for the tablet formulation in the European Union and in the European Economic Area countries Norway and Iceland.

On June 11, 2025, we announced that the U.S. Food and Drug Administration approved a new tablet formulation of BRUKINSA for all five approved indications.

On May 27, 2025, we announced our new name and completed the redomiciliation to Switzerland, marking a significant milestone in the Company's evolution.

FUTURE AND OUTLOOK

We were founded with the vision to create an integrated biopharmaceutical company to address challenges in the pharmaceutical industry, creating impactful medicines that will be affordable and accessible to far more patients around the world. We are uniquely built to address an increasingly challenged industry and improve R&D returns.

We have built a substantial global clinical team of more than 3,700 people on six continents, allowing us to run clinical trials predominantly without reliance on CROs. We believe independence from traditional CRO models allows us to execute more cost-efficient global clinical development and achieve faster time to clinical proof-of-concept. It also allows us to expand the reach of our clinical sites, which supports diverse participation and the collection of robust data across all patient demographics. Our demonstrated ability to complete large-scale, multi-regional clinical trials is an important strategic competitive advantage and addresses an immense challenge in the pharmaceutical industry.

We have built a highly productive and cost-effective oncology research teams with 1,200+ scientists, allowing us to drive serial innovation to enable sustained market leadership. Our efforts have been validated by commercial approvals, clinical data, and collaborations that have secured US$1.5 billion in collaboration payments to our company as of June 30, 2025. We design each research program with a differentiated biological hypothesis MoA, which has resulted in multiple commercially approved medicines and a pipeline of wholly-owned assets with potential for combinations and depth in key tumor types. We have invested in diverse technology platforms to pursue innovation, including CDAC protein degraders, bispecific antibodies, tri-specific antibodies, and ADCs allowing us access to diverse modalities and to advance science with urgency and agility. Our research and innovation capabilities are primed for discovering high-quality and impactful medicines for patients in a highly productive and cost-effective way.

We have built a strong commercial portfolio, with BRUKINSA and TEVIMBRA® driving global revenue.

Solidifying our Sustainable Hematology Franchise

Our hematology franchise is led by BRUKINSA, which is supported by a broad clinical program with over 7,000 patients enrolled in more than 30 countries and regions across more than 35 trials. We continue to solidify our leadership in hematology, utilizing BRUKINSA as our cornerstone asset. We are focused on lifecycle management to build a sustainable hematology franchise maximizing value for our company, shareholders and patients globally. BRUKINSA has allowed us to build a strong franchise in hematology-oncology and we plan to solidify our leadership in CLL with our wholly-owned, emerging as global best-in-class hematology pipeline consisting of sonrotoclax and our BTK CDAC, while amplifying our impact in other B-cell malignancies. We believe our BTK CDAC combinations with BRUKINSA and sonrotoclax show promise to meaningfully outperform fixed duration regimens in CLL, and our three differentiated molecules offer potential best-in-disease combinations to cover the entire CLL patient spectrum and insulate BeOne from end-of-lifecycle pricing pressure.

Expanding Access to Our PD-1 Inhibitor for Patients Worldwide and Building Global Commercial Capabilities to Support Prolific Solid Tumor Pipeline

Our solid tumor franchise is led by our anti-PD-1 monoclonal antibody, TEVIMBRA®, which is currently approved in the U.S., EU, China, Japan and other countries. We intend to expand TEVIMBRA's global footprint through ongoing submissions and approvals. We are also developing a high-concentration subcutaneous formulation of TEVIMBRA which we believe will be competitive in global markets. With TEVIMBRA and the potentially best-in-class solid tumor pipeline assets, we are well-positioned to build our solid tumor business and deliver innovative therapies and combinations to patients.

We have a global commercial organization to deliver medicines to patients around the globe. We have established commercial capabilities in key large commercial markets of the U.S., E.U and China, and continue our rapid expansion of capabilities into Asia Pacific, Latin America, and Middle East regions, driving the delivery of highly effective and differentiated medicines to patients around the globe. This has enabled a geographically diversified revenue mix and a truly global business.

Our business model is sustainable and results in strong global financial profile. We believe we are financially well-positioned with cash and cash equivalents of approximately US$2.8 billion as of June 30, 2025. For the six months ended June 30, 2025, our product revenue has grown 45% from our current portfolio and cornerstone assets, which we expect to grow continuously in 2025 and beyond. We achieved GAAP profitability for the first time in both the first and second quarters of 2025, and we generated positive free cash flow for the first time in the second quarter of 2025. We will continue to be thoughtful and strategic in how we deploy our capital, and consistent with previous collaborations, we will actively explore partnerships that strengthen our business. We are committed to generating long-term value for our shareholders.

FINANCIAL REVIEW

Results of Operations

The following table summarizes our results of operations for the six months ended June 30, 2025 and 2024:

	Six Months Ended June 30,		Change	
	2025	2024		%
	(US dollars in thousands)			
Revenues				
Product revenue, net	2,410,606	1,668,064	742,542	44.5%
Collaboration revenue	21,973	12,754	9,219	72.3%
Total revenues	2,432,579	1,680,818	751,761	44.7%
Cost of sales – product	329,608	263,067	66,541	25.3%
Gross profit	2,102,971	1,417,751	685,220	48.3%
Operating expenses				
Research and development	1,006,783	915,104	91,679	10.0%
Selling, general and administrative	997,201	871,156	126,045	14.5%
Total operating expenses	2,003,984	1,786,260	217,724	12.2%
Income (loss) from operations	98,987	(368,509)	467,496	(126.9)%
Interest income, net	9,345	29,385	(20,040)	(68.2)%
Other income (expense), net	12,117	(10,222)	22,339	(218.5)%
Income (loss) before income taxes	120,449	(349,346)	469,795	(134.5)%
Income tax expense	24,859	22,209	2,650	11.9%
Net income (loss)	95,590	(371,555)	467,145	(125.7)%

Revenue

Total revenue increased to US$2,432.6 million, or 44.7%, for the six months ended June 30, 2025, from US$1,680.8 million for the six months ended June 30, 2024, primarily due to increased sales of our internally developed products, BRUKINSA and tislelizumab, as well as increased sales of in-licensed products, most notably from the Amgen products.

Net product revenues consisted of the following:

	Six Months Ended June 30,		Changes	
	2025	2024		%
	(US dollars in thousands)			
BRUKINSA®	1,741,504	1,125,914	615,590	54.7%
TEVIMBRA®	364,688	303,687	61,001	20.1%
XGEVA®	151,741	98,435	53,306	54.2%
BLINCYTO®	49,493	33,497	15,996	47.8%
KYPROLIS®	39,144	30,047	9,097	30.3%
POBEVCY®	24,987	28,205	(3,218)	(11.4)%
Other	39,049	48,279	(9,230)	(19.1)%
Total product revenue	2,410,606	1,668,064	742,542	44.5%

Net product revenue increased 44.5% to US$2,410.6 million for the six months ended June 30, 2025, compared to US$1,668.1 million in the prior-year period, primarily due to increased sales of BRUKINSA globally, driven by continued growth in the U.S. and Europe. In addition, product revenues in the six months ended June 30, 2025 were positively impacted by sales of TEVIMBRA and in-licensed products from Amgen, primarily XGEVA®.

Global sales of BRUKINSA totaled US$1,741.5 million in the six months ended June 30, 2025, representing a 54.7% increase compared to the prior-year period. U.S. sales of BRUKINSA totaled US$1,246.9 million in the six months ended June 30, 2025, compared to US$830.8 million in the prior-year period, representing growth of 50.1%, driven primarily by robust demand growth across all indications and modest benefit due to net pricing. BRUKINSA continues to maintain its leading new patient share across the BTKi class due to its differentiated, best-in-class clinical profile. BRUKINSA sales in Europe totaled US$266.4 million in the six months ended June 30, 2025, representing growth of 79.7% driven by increased market share across all major European markets, including Germany, Italy, Spain, France and the UK. BRUKINSA revenue in China totaled US$164.4 million, representing growth of 35.8%. BRUKINSA rest of world revenue totaled US$63.9 million in the six months ended June 30, 2025, representing growth of 147.2% compared to the prior-year period.

Revenue for TEVIMBRA totaled US$364.7 million in the six months ended June 30, 2025, compared to US$303.7 million in the prior-year period, representing a 20.1% increase.

Revenue for Amgen products in China totaled US$240.4 million in the six months ended June 30, 2025, compared to US$162.0 million in the prior-year period, driven primarily by increased XGEVA® sales volume.

Collaboration revenue totaled US$22.0 million and US$12.8 million for the six months ended June 30, 2025 and 2024, respectively, primarily related to revenue generated under the Novartis broad markets marketing and promotion agreement and royalty revenue under the Amgen collaboration.

Gross Margin

Gross margin on product sales increased to US$2,081.0 million for the six months ended June 30, 2025, compared to US$1,405.0 million in the prior-year period, primarily due to increased product revenue in the current year period. Gross margin as a percentage of product sales increased to 86.3% for the six months ended June 30, 2025, from 84.2% in the comparable period of the prior year. The gross margin percentage increased due to a proportionally higher sales mix of global BRUKINSA compared to other products in our portfolio. Gross margin also benefited from cost of sales productivity improvements for both BRUKINSA and TEVIMBRA. On an adjusted basis, which does not include depreciation and amortization, gross margin as a percentage of product sales increased to 86.9%, from 84.7% in the comparable period of the prior year.

Research and Development Expense

Research and development expense increased by US$91.7 million, or 10.0%, to US$1,006.8 million for the six months ended June 30, 2025 from US$915.1 million for the six months ended June 30, 2024. The following table summarizes external clinical, external non-clinical and internal research and development expense for the six months ended June 30, 2025 and 2024, respectively:

	Six Months Ended June 30,		Changes	
	2025	2024		%
	(US dollars in thousands)			
External research and development expense:				
Cost of development programs	352,613	247,633	104,980	42.4%
Upfront license and development milestone fees	500	46,528	(46,028)	(98.9)%
Amgen co-development expense[1]	47,146	35,966	11,180	31.1%
Total external research and development expenses	400,259	330,127	70,132	21.2%
Internal research and development expenses	606,524	584,977	21,547	3.7%
Total research and development expenses	1,006,783	915,104	91,679	10.0%
Adjusted research and development expenses[2]	865,252	787,949	77,303	9.8%

1. Our co-funding obligation for the development of the pipeline assets under the Amgen collaboration for the six months ended June 30, 2025 totaled US$92.7 million, of which US$47.1 million was recorded as R&D expense. The remaining US$45.6 million was recorded as a reduction of the R&D cost share liability.

2. Adjusted research and development expense is intended to provide investors and others with information about our performance without the effect of items that, by their nature, tend to obscure core operating results due to potential variability across periods based on the timing, frequency and magnitude of such items. Refer to Non-GAAP Financial Measures and Non-GAAP Reconciliation in this MD&A for more information about, and a detailed reconciliation of, these items.

The increase in external research and development expenses in the six months ended June 30, 2025 was primarily attributable to an increase in external costs of development programs primarily due to advancing preclinical programs into the clinic and early clinical programs into late stage, including Sonrotoclax (BCL2i), offset by lower development upfront and milestone fees.

Internal research and development expense increased US$21.5 million, or 3.7%, to US$606.5 million and was primarily attributable to the expansion of our global development organization and our clinical and preclinical drug candidates, as well as our continued efforts to internalize research and clinical trial activities and control spend.

Selling, General and Administrative Expense

	Six Months Ended June 30,		Changes	
	2025	2024		%
	(US dollars in thousands)			
Selling, general and administrative expenses	997,201	871,156	126,045	14.5%
Adjusted selling, general and administrative expenses[1]	837,166	736,068	101,098	13.7%

1. Adjusted selling, general and administrative expense is intended to provide investors and others with information about our performance without the effect of items that, by their nature, tend to obscure core operating results due to potential variability across periods based on the timing, frequency and magnitude of such items. Refer to Non-GAAP Financial Measures and Non-GAAP Reconciliation in this MD&A for more information about, and a detailed reconciliation of, these items.

Selling, general and administrative expense increased by US$126.0 million, or 14.5%, to US$997.2 million, for the six months ended June 30, 2025, from US$871.2 million for the six months ended June 30, 2024. The increase was primarily attributable to continued investment in global commercial expansion primarily in the U.S. and Europe. Selling, general and administrative expenses as a percentage of product sales were 41.4% for the six months ended June 30, 2025 compared to 52.2% in the prior-year period. We expect continued investment in selling and marketing activities as our product sales increase.

Interest Income, Net

Interest income, net decreased by US$20.0 million, or 68.2%, to US$9.3 million for the six months ended June 30, 2025, from US$29.4 million for the six months ended June 30, 2024. The decrease in interest income was primarily attributable to lower interest rates earned on our cash and cash equivalents. Interest expense increased resulting from higher interest rates on debt balance and lower interest capitalized related to completion of certain phases of our Hopewell facility.

Other Income (Expense), Net

Other income, net was US$12.1 million for the six months ended June 30, 2025, primarily due to foreign exchange gains and government subsidy income, partially offset by unrealized losses on our equity investments. For the six months ended June 30, 2024, other expense, net was US$10.2 million, primarily due to foreign exchanges losses resulting from the strengthening of the U.S. dollar compared to the RMB and the revaluation impact of RMB-denominated deposits held in U.S. functional currency subsidiaries.

Income Tax Expense

Income tax expense increased to US$24.9 million for the six months ended June 30, 2025, from US$22.2 million for the six months ended June 30, 2024. The income tax expense for the six months ended June 30, 2025 was primarily attributable to current Switzerland tax expense based on year to date earnings, current China tax expense due to certain non-deductible expenses, offset by net discrete adjustments of approximately US$8.7 million, primarily related to updated provision estimates for R&D tax credits. The income tax expense for the six months ended June 30, 2024 was primarily attributable to current U.S. tax expense determined after other special tax deductions and research and development tax credits, current Switzerland tax expense based on year to date earnings, and current China tax expense due to certain non-deductible expenses.

On July 4, 2025, the reconciliation bill (H.R. 1), commonly referred to as the One Big Beautiful Bill Act ("OBBBA"), was signed into law and includes a broad range of tax reform provisions that may affect our financial results. The OBBBA allows an elective deduction for domestic research and development expenses, a reinstatement of elective 100% first-year bonus depreciation, and a more favorable tax rate on foreign-derived deduction eligible Income. We are in the process of evaluating the impact of the OBBBA on our consolidated financial statements.

Net Income (Loss) and Earnings Per Share

U.S. GAAP net income improved for the six months ended June 30, 2025, as compared to the prior-year period loss, primarily attributable to revenue growth and improved operating leverage.

For the six months ended June 30, 2025, basic and diluted earnings per share was US$0.07 per share and $0.89 and $0.85 per ADS, respectively, compared to basic loss of US$0.27 per share and US$3.56 per ADS in the prior-year period.

Non-GAAP Reconciliation

	Six Months Ended June 30,	
	2025	2024
	(US dollar in thousands)	
Reconciliation of GAAP to adjusted cost of sales – products:		
GAAP cost of sales – products	329,608	263,067
Less: Depreciation	5,934	5,029
Less: Amortization of intangibles	6,922	2,360
Less: Other	893	–
Adjusted cost of sales – products	315,859	255,678
Reconciliation of GAAP to adjusted research and development:		
GAAP research and development	1,006,783	915,104
Less: Share-based compensation expenses	106,159	93,451
Less: Depreciation	35,372	33,704
Adjusted research and development	865,252	787,949
Reconciliation of GAAP to adjusted selling, general and administrative:		
GAAP selling, general and administrative	997,201	871,156
Less: Share-based compensation expenses	139,845	125,957
Less: Depreciation	20,162	9,131
Less: Amortization of intangibles	28	–
Adjusted selling, general and administrative	837,166	736,068
Reconciliation of GAAP to adjusted operating expenses		
GAAP operating expenses	2,003,984	1,786,260
Less: Share-based compensation expenses	246,004	219,408
Less: Depreciation	55,534	42,835
Less: Amortization of intangibles	28	–
Adjusted operating expenses	1,702,418	1,524,017

	Six Months Ended June 30,	
	2025	2024
	(US dollar in thousands)	
Reconciliation of GAAP to adjusted income (loss) from operations:		
GAAP income (loss) from operations	98,987	(368,509)
Plus: Share-based compensation expenses	246,004	219,408
Plus: Depreciation	61,468	47,864
Plus: Amortization of intangibles	6,950	2,360
Plus: Other	893	–
Adjusted income (loss) from operations	414,302	(98,877)
Reconciliation of GAAP to adjusted net income (loss):		
GAAP net income (loss)	95,590	(371,555)
Plus: Share-based compensation expenses	246,004	219,408
Plus: Depreciation	61,468	47,864
Plus: Amortization of intangibles	6,950	2,360
Plus: Other	893	–
Plus: Impairment of equity investments	15,494	–
Plus: Discrete tax items	(8,737)	2,403
Plus: Income tax effect of non-GAAP adjustments	(28,703)	(23,082)
Adjusted net income (loss)	388,959	(122,602)
Reconciliation of GAAP to adjusted EPS – basic (in US$)		
GAAP earnings (loss) per share – basic	0.07	(0.27)
Plus: Share-based compensation expenses	0.18	0.16
Plus: Depreciation	0.04	0.04
Plus: Amortization of intangibles	0.00	0.00
Plus: Other	0.00	0.00
Plus: Impairment of equity investments	0.01	0.00
Plus: Discrete tax items	(0.01)	0.00
Plus: Income tax effect of non-GAAP adjustments	(0.02)	(0.02)
Adjusted earnings (loss) per share – basic	0.28	(0.09)

	Six Months Ended June 30,	
	2025	2024
	US dollar	
Reconciliation of GAAP to adjusted EPS – diluted		
GAAP earnings (loss) per share – diluted	0.07	(0.27)
Plus: Share-based compensation expenses	0.17	0.16
Plus: Depreciation	0.04	0.04
Plus: Amortization of intangibles	0.00	0.00
Plus: Other	0.00	0.00
Plus: Impairment of equity investments	0.01	0.00
Plus: Discrete tax items	(0.01)	0.00
Plus: Income tax effect of non-GAAP adjustments	(0.02)	(0.02)
Adjusted earnings (loss) per share – diluted	0.27	(0.09)
Reconciliation of GAAP to adjusted earnings (loss) per ADS – basic		
GAAP earnings (loss) per ADS – basic	0.89	(3.56)
Plus: Share-based compensation expenses	2.29	2.10
Plus: Depreciation	0.57	0.46
Plus: Amortization of intangibles	0.06	0.02
Plus: Other	0.01	0.00
Plus: Impairment of equity investments	0.14	0.00
Plus: Discrete tax items	(0.08)	0.02
Plus: Income tax effect of non-GAAP adjustments	(0.27)	(0.22)
Adjusted earnings (loss) per ADS – basic	3.61	(1.17)
Reconciliation of GAAP to adjusted earnings (loss) per ADS – diluted		
GAAP earnings (loss) per ADS – diluted[1]	0.85	(3.56)
Plus: Share-based compensation expenses	2.20	2.10
Plus: Depreciation	0.55	0.46
Plus: Amortization of intangibles	0.06	0.02
Plus: Other	0.01	0.00
Plus: Impairment of equity investments	0.14	0.00
Plus: Discrete tax items	(0.08)	0.02
Plus: Income tax effect of non-GAAP adjustments	(0.26)	(0.22)
Adjusted earnings (loss) per ADS – diluted	3.48	(1.17)

- For the second quarter of 2024, GAAP diluted loss per ADS includes US$0.02 loss per ADS attributable to the dilutive ADS outstanding for purposes of this reconciliation. As the Company was in a GAAP net loss position no diluted weighted average shares outstanding were calculated for US GAAP purposes.

	Six Months Ended June 30,	
	2025	2024
	(US dollar in thousands)	
Free Cash Flow (Non-GAAP):		
Net cash provided by (used in) operating activities (GAAP)	307,680	(404,160)
Less: Purchases of property, plant and equipment	(100,233)	(266,528)
Free Cash Flow (Non-GAAP)	207,447	(670,688)

Discussion of Certain Key Balance Sheet Items

Cash, cash equivalents, restricted cash

As of June 30, 2025, the Company's cash, cash equivalents, restricted cash primarily comprised of (1) approximately US$1.1 billion denominated in US dollars; (2) approximately RMB10.0 billion (equivalent to approximately US$1.4 billion) denominated in Renminbi; and (3) approximately US$281.1 million denominated in Australian dollar, Euro and other currencies**.**

Accounts receivable, net

Accounts receivable increased by 14.0% from US$676.3 million as of December 31, 2024 to US$770.8 million as of June 30, 2025, primarily due to the increased sales of our internally-developed products.

Prepaid expenses and other current assets

Prepaid expenses and other current assets increased by 45.4% from US$192.9 million as of December 31, 2024 to US$280.5 million as of June 30, 2025. The increase was primarily due to: (i) the increase of other receivables associated with the employee tax payments on share-based compensation; (ii) the increase of prepaid research and development costs.

Property, plant and equipment, net

The property, plant and equipment, net increased by 2.4% from US$1,578.4 million as of December 31, 2024 to US$1,615.8 million as of June 30, 2025, primarily attributable to our ongoing buildout of the Company's manufacturing and clinical R&D campus in Hopewell.

Intangible assets, net

The intangible assets, net increased by 27.0% from US$51.1 million as of December 31, 2024 to US$64.9 million as of June 30, 2025, primarily attributable to the capitalization of the distribution right.

Accounts payable

Accounts payable includes amounts due to third parties and totaled US$360.8 million and US$405.0 million as of June 30, 2025 and December 31, 2024.

The following table sets forth an aging analysis of accounts payable as of the dates indicated, which is based on invoice date:

	As of	
	June 30, 2025	**December 31, 2024**
	US$'000	**US$'000**
Within 1 year	360,371	404,738
Over 1 year	412	259
Total	360,783	404,997

Accrued expenses and other payables

Accrued expenses and other payables consist of the following as of June 30, 2025 and December 31, 2024:

	As of	
	June 30, 2025	**December 31, 2024**
	US$'000	**US$'000**
Revenue rebates and returns related	297,317	235,600
Compensation related	233,246	248,348
Individual income tax and other taxes	109,376	34,904
External research and development activities related	106,185	154,269
Commercial activities	99,749	77,530
Accrued general and administrative expenses	46,091	31,106
Other	16,918	21,956
Total	908,882	803,713

Accrued expenses and other payables increased by 13.1% from US$803.7 million as of December 31, 2024 to US$908.9 million as of June 30, 2025. The increase was primarily due to: (i) the increase of individual income tax from exercise of employee's share-based compensation awards; (ii) the increase of sales rebates and returns in line with increased sales volume of our internally developed products.

Debt

The company's total debt decreased by 6.2% from US$1,018.0 million as of December 31, 2024 to US$954.5 million as of June 30, 2025, primarily due to the decrease of both short-term and long-term debt during the period.

Liquidity and Capital Resources

The following table represents our cash and debt balances as of June 30, 2025 and December 31, 2024:

	As of	
	June 30, 2025	**December 31, 2024**
	(US dollars in thousands)	
Cash, cash equivalents and restricted cash	2,786,086	2,638,747
Total debt	954,485	1,018,013

To date, we have financed our operations and investments in long-term assets principally through proceeds from public and private offerings of our securities, proceeds from debt and our collaborations, and since the third quarter of 2024 cash flow from operations. Based on our current operating plan, we expect that our operating cash flows and existing cash and cash equivalents will enable us to fund our operating expenses and planned long-term investments for at least the next 12 months after the date that the financial statements included in this report are issued. We have also financed our operations and investments with proceeds from debt primarily incurred through various banks by both our subsidiaries and the Parent Company of US$954.5 million as of June 30, 2025. We paid down US$71.1 million of the debt in the six months ended June 30, 2025 using existing cash. The majority of those debt obligations, or approximately US$672.3 million, owed by BeOne Medicines Ltd. mature within the next 12 months. We believe we will have sufficient cash and cash equivalents and other sources of capital to be able to repay and/or refinance those debt obligations on a consolidated basis.

On December 15, 2021, we completed our initial public offering on the STAR Market of the Shanghai Stock Exchange (the "STAR Offering"). As required by the PRC securities laws, the net proceeds from the STAR Offering must be used in compliance with the planned uses as disclosed in the PRC prospectus as well as our proceeds management policy for the STAR Offering approved by our board of directors. As of June 30, 2025, we had cash remaining related to the STAR Offering proceeds of US$359.5 million.

The following table provides information regarding our cash flows for the six months ended June 30, 2025 and 2024:

	Six Months Ended June 30,	
	2025	2024
	(US dollars in thousands)	
Cash, cash equivalents and restricted cash at beginning of period	2,638,747	3,185,984
Net cash provided by (used in) operating activities	307,680	(404,160)
Net cash used in investing activities	(188,546)	(320,863)
Net cash provided by financing activities	1,248	185,310
Net effect of foreign exchange rate changes	26,957	(28,340)
Net increase (decrease) in cash, cash equivalents, and restricted cash	147,339	(568,053)
Cash, cash equivalents and restricted cash at end of period	2,786,086	2,617,931

Operating Activities

Cash provided by operating activities improved US$711.8 million in the six months ended June 30, 2025, versus the prior year period due to our significantly improved revenue and US$359.7 million of increase in gross margin in the current year period, offset by continued funding of our development pipeline and commercial operations, and increasing working capital to support our global expansion.

Investing Activities

Investing activities used US$188.5 million of cash in the six months ended June 30, 2025, compared to US$320.9 million in the prior year period due primarily to a decrease in capital expenditures, partially offset by an increase in acquired in-process research and development and regulatory milestone payments.

Financing Activities

Financing activities provided US$1.2 million of cash in the six months ended June 30, 2025, compared to US$185.3 million in the prior year period due primarily to a net reduction in debt borrowings in the current year period and higher payroll tax payments upon vesting of share-based compensation awards, partially offset by higher proceeds from option exercises and employee share purchase plan.

Our borrowing and repayment cycle is dictated by the short-term maturities of our debt and the ability to increase our borrowings, if necessary, is dependent on interest rates, credit spreads, bank lending capacity and other factors. We expect to repay approximately US$808.4 million of loans in the next 12 months and expect to be able to re-finance those on a consistent basis with our historical experience, with the cost of those borrowings depending on prevailing interest rates and credit spreads.

Effects of Exchange Rates on Cash

As noted above, we hold RMB denominated cash in our Parent Company (largely arising from the STAR Offering) and incur foreign currency gains or losses when remeasuring such cash to the U.S. dollar. In the six months ended June 30, 2025, we incurred realized gains on cash of US$6.5 million that is included in the reconciling items between net income and net cash provided by operating activities on the consolidated statements of cash flows primarily related to the remeasurement of RMB denominated cash to USD. The RMB denominated cash in our Parent Company, however, is required to be used to fund RMB denominated expenditures and thus foreign currency gains or losses on such cash does not affect our ability to fund those expenditures.

We also have substantial operations in China and Europe, where the functional currency is the RMB and Euro, and as such the net cash flows are translated to the U.S. dollar for financial reporting. This process generates translation gains and losses primarily on RMB-denominated cash held in China and Euro-denominated cash held in Europe that are included in the effects of foreign exchange rate changes on the consolidated statements of cash flows, as such translation gains and losses are excluded from cash flows from operating, investing and financing activities.

Future Liquidity and Material Cash Requirements

Our material cash requirements in the short- and long-term consist of the following operational, capital, and manufacturing expenditures, a portion of which contain contractual or other obligations. We plan to fund our material cash requirements with cash on hand.

Contractual and Other Obligations

The following table summarizes our significant contractual obligations as of the payment due date by period as of June 30, 2025:

	Payments Due by Period		
	Total	**Short Term**	**Long Term**
	(US dollars in thousands)		
Contractual obligations			
Operating lease commitments	79,054	10,608	68,446
Purchase commitments	130,087	105,910	24,177
Debt obligations	954,485	808,394	146,091
Interest on debt	39,869	28,533	11,336
Co-development funding commitment	242,916	220,869	22,047
Funding commitment	6,740	2,298	4,442
Capital commitments	62,029	62,029	–
Total	1,515,180	1,238,641	276,539

Operating Lease Commitments

We lease office facilities in the U.S. and Switzerland, and office and manufacturing facilities in China under non-cancelable operating leases expiring on various dates. Payments under operating leases are expensed on a straight-line basis over the respective lease terms. The aggregate future minimum payments under these non-cancelable operating leases are summarized in the table above.

Purchase Commitments

As of June 30, 2025, non-cancellable purchase commitments amounted to US$130.1 million, of which US$32.6 million related to minimum purchase requirements for supply purchased from contract manufacturers and US$97.5 million related to binding purchase obligations of inventory from Amgen. We do not have any minimum purchase requirements for inventory from Amgen.

Debt Obligations and Interest

Total debt obligations coming due in the next twelve months are US$808.4 million. Total long-term debt obligations are US$146.1 million. We have numerous financial and non-financial covenants on our debt obligations with various banks and other lenders. Some of these covenants include default and/or cross-default provisions that could require acceleration of repayment of loans in the event of default. However, our debt is primarily short-term in nature. Any acceleration would be a matter of months but may impact our ability to refinance debt obligations if an event of default occurs. As of June 30, 2025, we were in compliance with all covenants of our material debt agreements. See above regarding Liquidity and Capital Resources and Note 12 in the Notes to the Condensed Consolidated Financial Statements for further detail of our debt obligations.

Interest on bank loans is paid quarterly until the respective loans are fully settled. For the purpose of contractual obligations calculation, current interest rates on floating rate obligations were used for the remainder contractual life of the outstanding borrowings.

Co-Development Funding Commitment

Under the Amgen collaboration, we are responsible for co-funding global development costs for the licensed Amgen oncology pipeline assets up to a total cap of US$1.25 billion. We are funding our portion of the co-development costs by contributing cash and development services. As of June 30, 2025, our remaining co-development funding commitment was US$242.9 million.

Funding Commitment

Funding commitment represents our committed capital related to equity investments. As of June 30, 2025, our remaining capital commitment was US$6.7 million and is expected to be paid from time to time over the investment period.

Capital Commitments

We had capital commitments amounting to US$62.0 million for the acquisition of property, plant and equipment as of June 30, 2025, related to various facilities across the globe, including the manufacturing and clinical R&D campus in Hopewell, New Jersey.

Critical Accounting Policies and Significant Judgments and Estimates

Our discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenues, costs and expenses. We evaluate our estimates and judgments on an ongoing basis, and our actual results may differ from these estimates. These include, but are not limited to, estimating the useful lives of long-lived assets, estimating variable consideration in product sales and collaboration revenue arrangements, estimating the incremental borrowing rate for operating lease liabilities, identifying separate accounting units and the standalone selling price of each performance obligation in the Company's revenue arrangements, assessing the impairment of long-lived assets, valuation and recognition of share-based compensation expenses, realizability of deferred tax assets and the fair value of financial instruments. We base our estimates on historical experience, known trends and events, contractual milestones and other various factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.

There have been no material changes to our critical accounting policies as of and for the six months ended June 30, 2025, as compared to those described in the section titled "Part II – Item 7 – Management's Discussion and Analysis of Financial Condition and Results of Operations" included in our Annual Report on Form 10-K for the year ended December 31, 2024.

For new accounting policies adopted during the six months ended June 30, 2025, see "Part I – Item 1 – Financial Statements – Notes to the Condensed Consolidated Financial Statements – 1. Description of Business, Basis of Presentation and Consolidation and Significant Accounting Policies – Significant accounting policies" in this Quarterly Report on Form 10-Q.

Interest Risk

We are exposed to risk related to changes in interest rates on our outstanding borrowings. We had US$615.4 million of outstanding floating rate debt as of June 30, 2025. A 100-basis point increase in interest rates as of June 30, 2025 would increase our annual pre-tax interest expense by approximately US$6.2 million.

Foreign Currency Exchange Rate Risk

China Exchange Rate Regime

RMB is not freely convertible into foreign currencies for capital account transactions. The State Administration of Foreign Exchange, under the authority of the People's Bank of China, controls the conversion of RMB into foreign currencies. The value of RMB against the U.S. dollar and other currencies is affected by, among other things, changes in China's political and economic conditions and China's foreign exchange prices. Since 2005, the RMB has been permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies. The RMB compared to the U.S. dollar appreciated approximately 1.9% in the six months ended June 30, 2025 and depreciated approximately 2.8% in the year ended December 31, 2024, respectively. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the RMB and the U.S. dollar in the future.

Transactional Risk

We are exposed to foreign exchange risk arising from various currency exposures when we enter into transactions denominated in foreign currencies. Our reporting currency is the U.S. dollar, and our most significant functional currencies are the U.S. dollar and the RMB. A portion of our operating transactions and monetary assets and liabilities are in currencies other than the U.S. dollar and RMB, primarily the U.S. dollar against the RMB, Euro, and Australian dollar. During the six months ended June 30, 2025 and 2024, we recognized US$6.5 million of foreign exchange gains and US$13.5 million of foreign exchange losses, respectively, resulting from changes in the value of the U.S. Dollar compared to the RMB and the revaluation impact of RMB-denominated deposits held in U.S. dollar functional currency entities, including the Parent Company. As of June 30, 2025, the Parent Company held RMB-denominated deposits of US$128.9 million. A hypothetical 10% appreciation in the U.S. dollar exchange rate compared with the RMB as of June 30, 2025 would have resulted in an increase in foreign exchange loss of approximately US$11.7 million.

Translational Risk

We also face foreign currency exposure that arises from translating the results of our global operations to the U.S. dollar at exchange rates that have fluctuated from the beginning of the period, primarily the RMB against the U.S. dollar. A significant depreciation of the RMB against the U.S. dollar may significantly reduce the U.S. dollar equivalent of our foreign cash balances and trade receivables. Further, volatility in exchange rate fluctuations may have a significant impact on the foreign currency translation adjustments recorded in other comprehensive income (loss).

We have not used derivative financial instruments to reduce the effect of fluctuating currency exchange rates.

Effects of Inflation

Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our results of operations during the six months ended June 30, 2025.

Gearing Ratio

The gearing ratio of the Company, which was calculated by dividing total interest-bearing loans by total equity as of the end of the period, was 25.3% as of June 30, 2025, representing a decrease from 30.6% as of December 31, 2024, primarily due to the decrease of debt and the increase of equity.

Significant Investments Held

Except as disclosed in notes to the consolidated financial statements, we did not have other significant investments held as of June 30, 2025.

Future Plans for Material Investments and Capital Assets

Except as disclosed in notes to the consolidated financial statements, we did not have other plans for material investments and capital assets as of June 30, 2025.

Material Acquisitions and Disposals of Subsidiaries, Associates and Joint Ventures

Except as disclosed in notes to the consolidated financial statements, we did not have other material acquisitions and disposals of subsidiaries, associates and joint ventures during the six months ended June 30, 2025.

Employee and Remuneration Policy

As of the date of this announcement, we had a global team of over 11,000 employees. Most of our employees are full-time.The remuneration policy and package of the Company's employees are periodically reviewed. In addition to cash compensation and benefits, we may issue share options, share appreciation rights, restricted shares, restricted share units, unrestricted shares, performance share awards, cash-based awards and dividend equivalent rights to our employees in accordance with our equity plans. We also provide external and internal training programs to our employees. The packages were set by benchmarking with companies in similar industries and companies of similar size. The total remuneration cost incurred by the Company for the six months ended June 30, 2025 was US$1.0 billion (For the six months ended June 30, 2024: US$0.9 billion).

Pledge of Assets

As of June 30, 2025, we pledged restricted deposits of US$30.0 million (December 31, 2024: US$11.3 million) primarily consisting of cash deposits held in designated bank accounts for collateral for letters of credit and letter of guarantee, and land use right and certain property, plant and equipment with a total carrying amount of US$158.2 million (December 31, 2024: US$144.9 million) were secured for long-term bank loans.

Contingent Liabilities

As of June 30, 2025, we did not have any material contingent liabilities (as of December 31, 2024: nil).

Interim Dividend

The Board does not recommend any interim dividend for the six months ended June 30, 2025 (For the six months ended June 30, 2024: nil).

Recent Accounting Pronouncements

See Note 2 to our consolidated financial statements included in this announcement for information regarding recent accounting pronouncements.

OTHER INFORMATION

Compliance with the Corporate Governance Code

The Company is committed to maintaining and promoting stringent corporate governance. The principle of the Company's corporate governance is to promote effective internal control measures, uphold a high standard of ethics, transparency, responsibility and integrity in all aspects of business, to ensure that its affairs are conducted in accordance with applicable laws and regulations, and to enhance the transparency and accountability of the Board to the Company's shareholders.

The Board believes that good corporate governance standards are essential in providing a framework for the Company to safeguard the interests of shareholders, enhance corporate value and formulate its business strategies and policies.

During the Reporting Period, the Company has applied the principles in the Corporate Governance Code (the "Corporate Governance Code") as set out in Appendix C1 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "HK Listing Rules") which are applicable to the Company and complied with the code provisions in the Corporate Governance Code save for the following deviations.

Pursuant to code provision C.2.1 of the Corporate Governance Code, companies listed on the HKEX are expected to comply with, but may choose to deviate from, the requirement that the responsibilities of the Chairman and the Chief Executive Officer should be segregated and should not be performed by the same individual. We do not have a separate Chairman and Chief Executive Officer and Mr. John V. Oyler currently performs these two roles. Our Board believes that Mr. John V. Oyler is the director best suited to identify strategic opportunities and focus of the Board due to his extensive understanding of our business as a Co-Founder and our Chief Executive Officer. Our Board also believes that the combined role of Chairman and Chief Executive Officer can promote the effective execution of strategic initiatives and facilitate the flow of information between management and the Board. Our Board will continue to review and consider splitting the roles of Chairman and the Chief Executive Officer at a time when it is appropriate by taking into account the circumstances of our Company as a whole. Our Corporate Governance Guidelines provide the Board with the flexibility to choose the appropriate Board leadership structure of the Company based upon its view of what is in the best interest of the Company. Our Corporate Governance Guidelines also provide that if the same person holds the Chairman and Chief Executive Officer roles or if the Chairman does not otherwise qualify as independent, the independent directors may elect a lead director. Mr. Ranjeev Krishana, an independent non-executive director of the Company, currently serves as the lead director. The Board believes our current Board leadership structure will help ensure continuity of strong and effective leadership. The lead director has responsibilities that are set forth in our Corporate Governance Guidelines, including presiding at meetings of the Board at which the Chairman is not present, including executive sessions of the independent directors; consulting with management regarding Board meeting schedules, locations, agendas, and materials; and calling meetings of the independent and non-management directors, when appropriate.

Our Audit Committee is in compliance with Rule 3.21 of the HK Listing Rules and the Corporate Governance Code, except for the terms of reference required by paragraphs D.3.3 and D.3.7 of the Corporate Governance Code. However, the charter of our Audit Committee complies with the NASDAQ Listing Rules and the rules of the SEC. The primary duties of the Audit Committee are, among other things, to monitor the integrity of our financial statements and our compliance with legal and regulatory requirements as they relate to our financial statements and accounting matters, review the adequacy of our internal control over financial reporting, and review all related party transactions for potential conflict of interest situations and approving all such transactions. As of the date of this announcement, the Audit Committee comprises four independent non-executive directors, namely Ms. Shalini Sharp, Dr. Olivier Brandicourt, Mr. Anthony C. Hooper and Dr. Corazon (Corsee) D. Sanders. Ms. Shalini Sharp, being the chair of the Audit Committee, is appropriately qualified as required under Rules 3.10(2) and 3.21 of the HK Listing Rules. Effective as of March 1, 2025, Ms. Shalini Sharp has been appointed as the Chair of the Audit Committee. Mr. Anthony C. Hooper ceased to serve as the Chair of the Audit Committee but remains a member of the Audit Committee.

Our compensation committee (the "Compensation Committee") is in compliance with Rule 3.25 of the HK Listing Rules and the Corporate Governance Code, except for the terms of reference required by paragraph E.1.2 of the Corporate Governance Code. However, the charter of the Compensation Committee complies with the NASDAQ Listing Rules. The primary duties of the Compensation Committee are to annually review and make recommendations to the Board for submission to, and ratification by, the shareholders with respect to the maximum aggregate amount of compensation of the Board and the executive management team, evaluate the performance of our Chief Executive Officer, Chief Operating Officer and Chief Financial Officer and review and make recommendations to the Board regarding the terms of their compensation, and review and approve the compensation of our other executive officers and senior management, and review and approve matters relating to incentive-based compensation plans and equity-based plans. As of the date of this announcement, the Compensation Committee comprises three independent non-executive directors, namely Dr. Margaret Han Dugan, Mr. Ranjeev Krishana and Mr. Qingqing Yi. Dr. Margaret Han Dugan is the chair of the Compensation Committee.

Our nominating and corporate governance committee (the "Nominating and Corporate Governance Committee") is in compliance with the Corporate Governance Code, except for the terms of reference required by paragraph B.3.1 of the Corporate Governance Code. However, the charter of the Nominating and Corporate Governance Committee complies with the NASDAQ Listing Rules. The primary duties of the Nominating and Corporate Governance Committee are to annually evaluate the performance of the Board and Board's committees, annually review the structure, size, and composition (including the skills, knowledge, and experience) of the Board, develop and recommend to the Board criteria for board and committee membership, recommend to the Board the persons to be nominated for election as directors and to each of the Board's committees, and develop and recommend to the Board a set of corporate governance guidelines. During the Reporting Period, our Nominating and Corporate Governance Committee complied with Rule 3.27A of the HK Listing Rules, except the chair of our Nominating and Corporate Governance Committee fell vacant as the result of the passing away of Mr. Donald W. Glazer which did not meet the requirement under Rule 3.27A of the HK Listing Rules. Effective as of January 16, 2025, the Board appointed Ms. Shalini Sharp, an independent non-executive director of the Company, as a member of the Nominating and Corporate Governance Committee and appointed Mr. Anthony C. Hooper, an independent non-executive director of the Company, as the chair of the Nominating and Corporate Governance Committee. Upon the appointment of Mr. Anthony C. Hooper as the chair of the Nominating and Corporate Governance Committee, the Company has re-complied with Rule 3.27A of the HK Listing Rules in respect of the requirement regarding establishing a nomination committee chaired by the chairman of the board or an independent non-executive director. As of the date of this announcement, the Nominating and Corporate Governance Committee comprises four independent non-executive directors, namely Mr. Anthony C. Hooper, Mr. Michael Goller, Dr. Alessandro Riva and Ms. Shalini Sharp. Mr. Anthony C. Hooper is the chair of the Nominating and Corporate Governance Committee.

Except as disclosed above, the Company has complied with all of the provisions set out in the Corporate Governance Code during the Reporting Period.

The Board will continue to regularly review and monitor its corporate governance practices to ensure compliance with the Corporate Governance Code and maintain a high standard of corporate governance practices of the Company.

Compliance with Policies Equivalent to the Model Code for Securities Transactions by Directors of Listed Issuers

Except as disclosed below, the Company has adopted its own insider dealing policies on terms no less exacting than those in the Model Code for Securities Transactions as set out in Appendix C3 to the HK Listing Rules (the "Model Code") regarding the directors' dealings in the securities of the Company.

Pursuant to Rule B.8 of the Model Code, a director must not deal in any securities of the issuer without first notifying in writing the chairman or a director (otherwise than himself) designated by the board for the specific purpose and receiving a dated written acknowledgement. Under the Company's insider dealing policies, the General Counsel of the Company, has been designated as the insider trading compliance officer whom a director who intends to deal in the Company's securities must notify. Our Board believes that our insider trading compliance officer, despite not being a member of the Board, is able to carry out his duties properly and competently in accordance with the Company's insider dealing policies, the terms of which are otherwise no less exacting than those in the Model Code.

Having made specific enquiry of all the Directors, all the Directors confirmed that they have strictly complied with the required standards set out in the Company's own insider dealing policies throughout the Reporting Period.

Purchase, Sale or Redemption of the Company's Listed Securities

On May 21, 2025, the Company issued 133,000,000 shares to BG NC 2, Ltd, a wholly-owned subsidiary of the Company, for the purpose of satisfying outstanding equity awards granted by the Company pursuant to the Fourth Amended and Restated 2016 Share Option and Incentive Plan (as amended from time to time) under the available scheme mandate limit as approved by the shareholders of the Company. For details, please refer to the Company's announcement dated May 14, 2025 and Next Day Disclosure Return dated May 22, 2025.

Save as disclosed above, during the Reporting Period, neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities (including any sale of treasury shares (as defined under the HK Listing Rules)).

Disclosure of Changes in Directors' Information Pursuant to Rule 13.51(B)(1) of the HK Listing Rules

Upon specific enquiry by the Company and following confirmations from the Directors, save as disclosed hereunder, there is no change in the information of the directors required to be disclosed pursuant to Rule 13.51B(1) of the HK Listing Rules during the Reporting Period and up to the date of this announcement. The change of the Directors' information is set out below:

Directors	**Changes in Positions held with the Company**
Mr. Anthony C. Hooper	Appointed as the chair of the Nominating and Corporate Governance Committee effective January 16, 2025; ceased to serve as the chair of the Audit Committee but remains as a member of the Audit Committee effective March 1, 2025.
Ms. Shalini Sharp	Appointed as a member of the Nominating and Corporate Governance Committee effective January 16, 2025; appointed as the chair of the Audit Committee effective March 1, 2025.

Use of Net Proceeds from Amgen

On January 2, 2020, the Company sold 15,895,001 ADSs, representing 206,635,013 ordinary shares of the Company and approximately 20.5% ownership stake in the Company's outstanding shares as at the same date, to Amgen for aggregate cash proceeds of US$2,779,241,000, or US$174.85 per ADS, pursuant to the share purchase agreement entered into by the Company and Amgen on October 31, 2019 in connection with the Amgen Collaboration Agreement, as amended ("Amgen SPA"). The subscription price represents: (a) a 36% premium to the 30-day volume weighted average price of the Company's ADSs as of October 30, 2019, the day prior to the date of the Amgen SPA; (b) assuming a conversion rate of US$1.00: HK$7.84, a 26% premium to the closing price of the Company's ordinary shares as quoted on the HKEX on October 31, 2019, the date of the Amgen SPA; (c) a 26% premium to the closing price of the Company's ADSs on the NASDAQ on October 31, 2019.

The net proceeds from the sale of the shares have been and will be utilized in accordance with the purposes set out in the proxy statement/circular of the Company dated November 29, 2019. The table below sets out the planned applications of the net proceeds and actual usage up to June 30, 2025:

Use of proceeds	Planned applications (US dollars in thousands)	Percentage of total net proceeds (%)	Actual usage up to December 31, 2024 (US dollars in thousands)	Actual usage up to June 30, 2025 (US dollars in thousands)	Unutilized net proceeds as of June 30, 2025 (US dollars in thousands)
To fund business operations[(a)]	2,779,241	100%	2,357,788	2,440,274	338,967

Note (a): To fund the Company's development obligations under the Amgen Collaboration Agreement by contributing cash and development services up to a total cap of approximately US$1.25 billion, the development, manufacturing and commercialization of the Company's internally developed drug candidates, expansion of the Company's commercialization activities, and for future capacity expansion and general corporate use, as appropriate, as previously disclosed in the Company's proxy statement/circular dated November 29, 2019.

The Company plans to gradually utilize the remaining net proceeds in accordance with such intended purposes depending on actual business, which is expected to be fully utilized by 2026. For further details, please refer to the announcements of the Company dated November 1, 2019, December 9, 2019, and January 3, 2020.

Use of Net Proceeds from STAR Offering

On December 15, 2021, the Company completed the STAR Offering on the STAR Market of the Shanghai Stock Exchange. The shares offered in the STAR Offering were issued to and subscribed for by permitted investors in China in Renminbi ("RMB Shares") pursuant to the general mandate to issue shares, which was approved by the shareholders at the Company's 2021 annual general meeting of shareholders held on June 16, 2021. The public offering price of the RMB Shares was RMB192.60 per RMB Share, which equates to HK$234.89 per ordinary share and US$391.68 per ADS. In this offering, the Company sold 115,055,260 RMB Shares. The RMB Shares are not fungible with the ordinary shares of the Company listed on the HKEX or with the ADSs representing the Company's ordinary shares listed on the NASDAQ. Net proceeds after deducting underwriting commission and offering expenses were US$3,392,616,000. The net proceeds from the STAR Offering have been and will be utilized in accordance with the purposes set out in the prospectus of the STAR Offering (the "STAR Prospectus"), including (i) clinical development and research project, (ii) research and development center construction, (iii) bio-manufacturing plant construction, (iv) sales and marketing force expansion, and (v) working capital and general corporate purposes. On November 10, 2023, the Board approved to adjust the amount of proceeds to be invested in each subcategory projects under the "clinical development and research project". As required by the PRC securities laws, the net proceeds from the STAR Offering must be used in strict compliance with the planned uses as disclosed in the STAR Prospectus as well as the Company's proceeds management policy for the STAR Offering approved by the Board.

For details, please refer to the Company's announcements dated November 16, 2020, January 29, 2021, April 20, 2021, May 14, 2021, June 1, 2021, June 21, 2021, June 28, 2021, June 30, 2021, July 9, 2021, July 28, 2021, October 15, 2021, November 16, 2021, November 23, 2021, November 24, 2021, November 29, 2021, November 30, 2021, December 2, 2021, December 6, 2021, December 7, 2021, December 13, 2021, December 21, 2021, December 28, 2021, April 29, 2022, June 27, 2022, August 30, 2022, September 28, 2022, April 25, 2023, August 29, 2023, November 13, 2023, April 26, 2024, August 29, 2024, November 12, 2024, April 28, 2025 and the circular dated April 30, 2021 of the Company.

As of June 30, 2025, net proceeds amounting to RMB19.7 billion had been utilized, and the remaining RMB2.0 billion will be gradually utilized in accordance with such intended purposes depending on actual business needs, and are expected to be fully utilized within five years after the completion of STAR Offering. The table below sets out the planned applications of the net proceeds and actual usage up to June 30, 2025:

Use of proceeds	Planned applications RMB'000	Actual usage up to December 31, 2024 RMB'000	Actual usage up to June 30, 2025 RMB'000	Unutilized net proceeds as of June 30, 2025 RMB'000
Clinical Development and Research Projects	13,245,940	10,045,510	11,732,185	1,513,755
R&D Center Construction	467,700	485,741	488,681	(20,981)*
Bio-Manufacture Plant Construction	150,000	153,451	153,451	(3,451)*
Sales & Marketing Force Expansion	136,360	143,560	143,560	(7,200)*
Replenishment of Working Capital	6,000,000	5,624,969	5,666,066	333,934
Excess of Proceeds	1,630,155	1,467,000	1,467,000	163,155
Total	21,630,155	17,920,231	19,650,943	1,979,212

* The excess over the planned applications for R&D Center Construction, Bio-Manufacture Plant Construction and Sales & Marketing Force Expansion were provided by interest income from the STAR Offering proceeds.

Audit Committee Review of Financial Statements

Our Audit Committee reviews the adequacy of our internal controls to ensure that our internal control system is effective in identifying, managing and mitigating risks involved in our business operations. As of the date of this announcement, the Audit Committee consists of four independent non-executive directors, namely Ms. Shalini Sharp, Dr. Olivier Brandicourt, Mr. Anthony C. Hooper and Dr. Corazon (Corsee) D. Sanders. Ms. Shalini Sharp, being the chair of the Audit Committee, is appropriately qualified as required under Rules 3.10(2) and 3.21 of the HK Listing Rules. Effective as of March 1, 2025, Ms. Shalini Sharp has been appointed as the Chair of the Audit Committee. Mr. Anthony C. Hooper ceased to serve as the Chair of the Audit Committee but remains a member of the Audit Committee.

The Audit Committee has reviewed the unaudited consolidated financial statements and interim results of the Company for the six months ended June 30, 2025. The Audit Committee has also discussed matters with respect to the accounting policies and practices adopted by the Company and internal control with members of senior management and the external auditor of the Company, Ernst & Young.

Other Board Committees

In addition to the Audit Committee, the Company has a Nominating and Corporate Governance Committee, a Compensation Committee, a Scientific Advisory Committee and a Commercial and Medical Affairs Advisory Committee.

Change of Domicile and Continuation; Adoption of Proposed Swiss Articles; Appointment of Swiss Auditor; and Change of English name

At the extraordinary general meeting of the Company held on April 28, 2025 (the "EGM"), the shareholders of the Company (the "Shareholders") have approved (i) the Company's de-registration in the Cayman Islands and the Company's continuation as a stock corporation in Switzerland (the "Continuation"); (ii) the adoption of the proposed Swiss articles in compliance with the laws of Switzerland (the "Proposed Swiss Articles"); and (iii) the appointment of Ernst & Young AG to serve as the Company's statutory auditor (for Swiss legal purposes) until the Company's first annual general meeting following the completion of the Continuation and provide related audit services (the "Appointment of Swiss Auditor") and the authorization to the Board to fix the remuneration of Ernst & Young AG.

The Company's Continuation to Switzerland as a stock corporation under the laws of Switzerland became effective on May 27, 2025 (Swiss time). With effect from the Continuation becoming effective, the Proposed Swiss Articles and the Appointment of Swiss Auditor became effective on May 27, 2025 (Swiss time). Subsequent to the adoption of the Proposed Swiss Articles, which incorporated the new English name of the Company of "BeOne Medicines Ltd.", the English name of the Company has changed from "BeiGene, Ltd." to "BeOne Medicines Ltd." (the "Change of English Name of the Company"), with effect from May 27, 2025 (Swiss Time). The Chinese name of the Company and the stock code of the Company on the HKEX remain unchanged. For details, please refer to the Company's announcement dated May 27, 2025.

Important Events after the Reporting Period

Save as disclosed above, no important events affecting the Company occurred since June 30, 2025 and up to the date of this announcement.

Publication of Interim Results and Interim Report

This interim results announcement is published on the website of the HKEX (www.hkexnews.hk) and the website of the Company (https://beonemedicines.com/). The interim report of the Company for the six months ended June 30, 2025 will be published on the aforesaid websites in due course.

By order of the Board
BeOne Medicines Ltd.
Mr. John V. Oyler
Chairman

Hong Kong, August 28, 2025

As of the date of this announcement, the Board of Directors of the Company comprises Mr. John V. Oyler as Chairman and Executive Director, Dr. Xiaodong Wang as Non-executive Director, and Dr. Olivier Brandicourt, Dr. Margaret Han Dugan, Mr. Michael Goller, Mr. Anthony C. Hooper, Mr. Ranjeev Krishana, Dr. Alessandro Riva, Dr. Corazon (Corsee) D. Sanders, Ms. Shalini Sharp and Mr. Qingqing Yi as Independent Non-executive Directors.